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ABSTRACT 
Epithelial ovarian cancer (EOC) is the most common gynecologic malignancy 
worldwide. EOC has a notably poor prognosis, owing to the fact that patients are 
frequently diagnosed at a late stage after the disease has significantly progressed. 
While many patients typically respond well to frontline platinum-based chemotherapy, 
the tumor becomes chemoresistant when a recurrence follows within five years. 
Therefore, there is an urgent need for the discovery of non-invasive early detection 
biomarkers and novel targeted therapies. 
Human Epididymis Protein 4 (HE4) is a secretory protein that is encoded by the gene 
whey acidic protein (WAP)-four disulfide core domain protein 2. The WAP domain 
family is a conserved motif that is inherit of many antiproteases. HE4 was initially 
found to be a component of the innate immune defenses of multiple epithelia and to 
function in epithelial host defense, through the promotion of mucosal surfaces first 
line of defense. HE4 is highly overexpressed in EOC and has been identified as a 
novel clinical biomarker. Clinical and translational studies have established HE4 as a 
contributor to tumorigenesis and chemoresistance in EOC. However, the exact 
processes in which HE4 promotes pathogenesis is unclear. The driving hypothesis of 
this thesis is that HE4 represents a novel targeted therapy due to its established role 
EOC tumorigenesis and suggested function in innate immunity. This evidence 
underlies the goals of this dissertation which are to elucidate the precise mechanisms 
of HE4’s contribution in EOC pathogenesis and establish HE4’s role in tumor immune 
invasion. It is hoped that results from this investigation will ultimately aide in the 
  
development of a novel targeted therapy against HE4 that can modulate tumor 
pathogenesis as well as the tumor immune response.  
In manuscript I, subtractive hybridization revealed that HE4 significantly suppresses 
expression of osteopontin (OPN) in peripheral blood mononuclear cells (PBMCs) 
which ultimately compromised their cytotoxicity against ovarian cancer cells. Ovarian 
cancer cells exhibited enhanced proliferation in conditioned media from HE4-exposed 
PBMCs and this effect was attenuated by the addition of recombinant OPN and OPN -
inducible cytokines (IL-12 and IFN-y). In addition, ovarian cancer cells and PBMCs 
with HE4 downregulation via short hairpin RNA (shRNA) were found to be 
increasingly more susceptible to cell death.  
In manuscript II, subtractive hybridization identified dual specificity phosphatase 6 
(DUSP6) as the most upregulated gene upon treatment with recombinant HE4 in 
PBMCs. Flow cytometry revealed that recombinant HE4 significantly upregulated 
DUSP6 levels specifically in CD8+ (cytotoxic T cell) and CD56+ (NK cell) 
populations. Exposure of these cells to HE4 led to an increase in ERK ½ 
phosphorylation, which was subsequently decreased upon DUSP6 inhibition. These 
results show that DUSP6 suppression of CD8+ and CD56+ lymphocyte toxicity is 
strongly enhanced by HE4. In co-culture of PBMCs and ovarian cancer cells, DUSP6 
inhibition attenuated the enhanced proliferation noted upon stimulation with HE4. The 
effect of DUSP6 inhibition was obliterated in CD8+ and CD56+ devoid PBMCs. 
In manuscript III, the role of DUSP6 and its relationship to HE4 in EOC was further 
elucidated. Increased DUSP6 levels were observed in ovarian cancer cells 
overexpressing HE4. siRNA-mediated downregulation of both HE4 and DUSP6 
  
revealed a corresponding decrease of either factor. Treatment with an allosteric 
DUSP6 inhibitor in combination with chemotherapeutic agents produced synergistic 
effects on the reduction of cell viability. These effects correlated with alterations in 
expression of ERK pathway mediated genes. Finally, it was found that DUSP6 was 
significantly overexpressed in serous EOC patient tissue compared to normal adjacent 
tissue.  
In manuscript IV it was determined from a small-scale proteomics study that 63 
proteins were found to interact more strongly with HE4, in HE4 overexpressing clones 
compared to null vector control. The protein found to exhibit the highest interaction in 
the HE4 clones was Septin-2, a GTP binding protein. Immunohistochemical analysis 
of Septin-2 in EOC patient tissue revealed that levels were overexpressed in cancer 
compared to normal and benign controls. To identify Septin-2’s role in EOC, stable 
knockdown cell lines were constructed using the ovarian cancer cell line SKOV3. 
Septin-2 knockdown cells demonstrated a significantly lowered proliferation rate 
compared wild-type (WT) and Plasmid C control cells. To better define the role of 
Septin-2 in EOC, proteomics was employed. Pathway analysis showed an enrichment 
in autophosphorylation, citric acid cycle, acetyl CoA/energy, and 
proteasomal/ubiquitin processes in Septin-2 knockout cells.  
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      PREFACE 
This dissertation adopts manuscript format. It is comprised of an introduction, 4 
manuscripts, and a conclusion. The format of each individual manuscript is in 
accordance with the journal that they were or will be submitted to.   
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Ovarian Cancer Incidence and Overall Survival  
Worldwide ovarian cancer has an incidence of 240,000 cases per year and an annual 
mortality rate of 152,000 [1]. This high mortality rate is largely due to that fact that in 
many cases ovarian cancer is detected at an advanced disease state. In addition, while 
the initial response rate to frontline chemotherapy is 60-80%, when the tumor recurs it 
eventually becomes unresponsive to traditional platinum-based chemotherapeutics[2]. 
Unfortunately, only a minority of patients with advanced stage disease achieve long 
term survival, as many patients will develop a recurrence within 12-18 months of 
completion of their primary treatment regimen [3].  Currently, the five year survival 
rate for ovarian cancer  is only 35%[4] , and these dire statistics have not improved 
significantly in the last 30 years[5]. 
 
1.2 Ovarian Cancer Subtypes  
Ovarian Cancer is divided into two major subtypes that depend on the tissue of origin. 
Non-epithelial ovarian cancer includes sex cord stromal, germ cell and non-specified 
ovarian cancers. Non-epithelial ovarian cancers only represent 10% of all ovarian 
cancer, [6]while the remaining 90% of cancer comprises epithelial ovarian cancer 
(EOC). EOC encompasses serous, transitional cell, mucinous, endometrioid, and clear 
cell ovarian cancer [7]. EOC is generally divided into two subtypes. Type 1 EOC are 
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considered more genetically stable, exhibit a slower tumor growth, and have disease 
contained within the ovary upon initial presentation. These cancers respond well to 
surgical intervention [7]. In contrast, type 2 EOC are characterized by an aggressive 
growth rate and are usually detected at an advanced stage of IIIC. High grade serous 
ovarian cancer (HGSOC) is the most common histological subtype of Type II EOC, 
representing nearly three quarters of all patients diagnosed with ovarian cancer [5].  
Seventy percent of the time, HGSOC is diagnosed at an advanced stage, leading to a 
poor prognosis [5].  Therefore, efforts have been made to develop novel 
prognostic/diagnostic methods and treatments to combat chemoresistance and improve 
overall survival for HGSOC.  
 
1.3 Current Ovarian Cancer Therapies  
Many women who present with elevated tumor markers and abnormal imaging 
typically proceed with primary debulking surgery. Initial surgery has three goals: 
diagnosis, staging and cytoreduction. Diagnosis is important as needle biopsies are 
not indicated for larger ovarian masses to prevent inadvertent spreading of the disease 
[8]. If a patient presents with significant comorbidities, clinicians will favor 
neoadjuvant chemotherapy over surgery. This approach minimizes surgical side 
effects for patients, as the tumor will be reduced following chemotherapy [8]. 
For the past 20 years, standard of care for women diagnosed with EOC is a primary 
frontline regimen of carboplatin and paclitaxel [9]. Carboplatin binds to DNA 
forming a platinum adduct and causes cell death [10]. Paclitaxel’s mechanism of 
action involves enhancing polymerization of tubulin, which stabilizes microtubules. 
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This stabilization results in the protection of the microtubule polymer from 
disassembly, and chromosomes are unable to achieve proper metaphase spindle 
organization. Ultimately, cells are halted in the G2/M phase of the cell cycle [11]. The 
overall response rate (ORR) for this combinational first line therapy is greater than 
75%. However, the majority of patients experience a recurrence and progression of 
disease. Once a recurrence occurs post-frontline therapy, the chemotherapy chosen for 
the patient is based on the platinum-free interval (PFI), which represents the time 
between the completion of the last platinum-based treatment and the detection of 
relapse [12]. Patients that have a PFI of six months or less are considered to be 
platinum-resistant, while patients that have a PFI greater than six months mark are 
considered platinum-sensitive. This distinction determines the second-line 
chemotherapy regimen used for the patient. [13]For platinum-sensitive patients 
experiencing recurrence, doxil or gemcitabine is added to a platinum regimen [12]. 
Doxil, or pegalyated doxorubicin(PLD) is  a polyethelyne-glycolate-coated  liposomal 
nanoparticle version of doxorubicin that exhibits enhanced drug delivery [14]. 
Doxorubicin is an antitumor antibiotic that promotes cell death by intercalation into 
DNA, disrupting DNA repair mediated by topisomerase II, and generating free 
radicals [15], Gemcitabeine is a pyrimidine antimetabolite that is inhibits tumor cell 
progression through the G1/S phase, halting DNA synthesis [14]. While platinum-
sensitive patients undoubtedly survive longer than patients who are initially platinum 
refractory, prognosis for these patients is still dismal. Platinum combinatorial 
therapies with doxil and gemcitabine exhibit a progression-free survival (PFS) of only 
11.3 and 8.6, respectively[16].  
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For platinum-resistant ovarian cancer, a non-platinum monotherapy is used with a 
non-curative goal of toxicity management, as prognosis in this group is poor. Patients 
in this group are frequently enrolled in clinical trials as a last attempt to control 
disease [17]. Topotecan, which works through inhibition of topoisomerase I, is a 
typical example of a salvage chemotherapy that is used in platinum resistant ovarian 
cancer [18].  The response rate of patients to this treatment is only 12-18%, and PFS 
is around 3-4 months[19,20].  Other  typical monotherapies for platinum-resistant 
second line EOC include doxil and bevacizumab [8]. Bevacizumab is a monoclonal 
antibody against vascular endothelial growth factor (VEGF), a major regulator of 
angiogenesis. Bevacizumab is approved in the recurrent setting, however it’s overall 
efficacy continues to be studied clinically in different chemotherapy lines and in 
combination with various treatment regimens [21]. While many large phase III trials 
report an increase in PFS for patients, this response does not correlate with an 
increased overall survival [21]. Other approved therapies in the maintenance setting 
are PARP inhibitors. While these inhibitors are approved for all patients, within this 
setting it has shown the most substantial benefit for patients who harbor the BRCA 
mutation—about 20-25% of the patient population [22,23].  Current clinical trials for 
EOC have largely focused on the immune checkpoint inhibition of programmed death 
receptor (PD-1) and it’s ligand PD-L1, however clinical trial results have suggested 
only a modest benefit [24]. Therefore, there is still a crucial treatment need for the 
non-BRCA patient population.  
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1.4 Detection Methods of EOC  
Early detection for EOC is difficult as many symptoms reported by patients, such as 
bloating and pelvic pain, are common symptoms of benign disease [25]. In addition, 
the sensitivity and specificity of pelvic examinations for EOC screening purposes 
within an asymptomatic population are poor. Therefore, diagnosis relies heavily on 
tumor markers and radiologic imaging [25]. Currently, there has not been an official 
recommendation for routine screening of asymptomatic women who are not high risk 
for development of an ovarian malignancy [26].  
Cancer antigen 125 (CA 125) is the most commonly used and validated tumor marker 
for the detection of EOC [27]. However, recently there has been sufficient research 
dedicated to an improvement of serum biomarkers for early detection of EOC. One 
biomarker that represents such improvement is Human Epididymis Protein 4 (HE4), 
which has been shown to have a higher specificity and comparable sensitivity to CA 
125 [28]. From these results, the risk of ovarian malignancy algorithm (ROMA) was 
established, which takes into account a woman’s menopausal status and incorporates 
preoperative serum levels of CA 125 and HE4. The ROMA score exhibits both a 
higher sensitivity and specificity than CA 125 alone [29].  As HE4 has been 
extensively studied clinically, its prognostic capabilities have also begun to be 
examined translationally.  
 
1.5 Molecular Functions of HE4   
HE4 is encoded by the Whey Acidic Protein (WAP) 4-disulphide core domain 
(WFDC2) gene. The WFDC2 transcript was thought to be exclusively expressed in 
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the epididymis and hence was originally proposed to be a specific marker for this 
tissue type [30]. WFDC2 is a member of the WAP domain, which is a conserved 
motif of 50 amino acids, including eight cysteine residues arranged as a 4-disulphide 
core [31]. While WAP proteins can display a variety of functions, the most 
comprehensively studied members of this family are the antiproteinases secretory 
leukocyte protease inhibitor (SLPI) and elafin. In addition to antiproteinase activities, 
both exhibit anti-inflammatory activities [32,33]. Due to the familial similarity of 
HE4, it has been proposed to function similarly to SLPI and elafin; however, this role 
has not been fully defined. In addition to HE4 overexpression in EOC tissue 
compared to normal and benign ovarian tissues [29,34],  it is also readily expressed in 
the oral cavity, nasopharynx and respiratory tract [35]. It was suggested that HE4 
functions in concert with other WAP domain family members to promote epithelial 
host defenses of the lung, nasal, and oral cavity; supporting the claim that HE4 plays 
a role in innate immune defenses [35].  HE4’s known molecular functions in EOC 
pathogenesis, particularly its role in promotion of cell proliferation, chemoresistance, 
metastasis and steroid biosynthesis, are comprehensively discussed in Chapter 2. 
 
 1.6 Problem Statement  
Challenges in both treatment and diagnosis of patients has led to strong efforts to 
elucidate new mechanisms of ovarian cancer pathology that can be used to develop 
novel targeted therapies, which are so desperately needed for this patient population. 
HE4 is a secretory protein that is overexpressed in EOC serum and tissue. Extensive 
studies have also shown that HE4 promotes EOC growth and chemoresistance. 
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However, the exact mechanisms of HE4 functions in EOC pathogenesis are not 
completely understood. In addition, while HE4 was initially found to play a role in 
innate immunity, its function in tumor immunity has yet to be defined. Therefore, 
further investigation of HE4’s mechanistic promotion of tumorigenesis is an 
important step to determine potential efficacy of a targeted anti-HE4 therapy for the 
treatment of EOC.  
 
The aim of this thesis research is to: 
1. Determine genes most suppressed by HE4 in immune cell populations and 
determine their involvement in muting the cytotoxic ability of immune cells 
toward ovarian cancer cells. 
2. Determine genes most induced by HE4 in immune cell populations and determine 
their involvement in muting the cytotoxic ability of immune cells toward ovarian 
cancer cells.  
3. Establish the significance of HE4 regulated genes in EOC pathogenesis. 
4. Define novel roles of proteins with an identified association with HE4 in EOC 
pathogenesis. 
 
1.7 Hypothesis  
The overall driving hypothesis of this investigation is that HE4 represents a novel 
therapeutic target due to its role in the promotion of EOC pathogenesis. While it is 
known that HE4 has a profound role in EOC diagnosis, its therapeutics capabilities 
have been largely undefined due to an incomplete identification of its signaling 
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network in EOC. Although the precise mechanism is unknown, it has been established 
that HE4 promotes tumorigenesis, chemoresistance, and metastasis in EOC. It has 
been previously proposed that HE4 plays a role in innate immunity; however, its 
immune functions in EOC have not been explored. The identification of novel genes 
and proteins at a global level in both EOC and immune cells could aide in the 
elucidation of a distinct HE4 signaling network. Thus, information obtained from 
these studies will ultimately contribute to a comprehensive understanding of the 
biological function of HE4 in EOC.  
In manuscript I, subtractive hybridization revealed that SPP1, which encodes for the 
protein OPN, was the gene most suppressed by HE4 expression in peripheral blood 
mononuclear cells (PBMCs). Flow cytometry was employed to determine specific 
immune cell populations within the PBMCs best characterized this relationship. 
Downstream effectors of the suppressed gene responses were measured via ELISA 
after stimulation with recombinant HE4. Ovarian cancer cells and PBMCs were then 
co-cultured and treated with recombinant HE4 to determine how this treatment 
compared to the effect of untreated PBMCs on ovarian cancer cell viability, cell 
migration, and proliferation. Immunohistochemistry examined populations of OPN 
positive T cells in human serous EOC tissue. Finally, HE4 siRNA was employed to 
determine how its downregulation would affect apoptosis in ovarian cancer cells co-
cultured with PBMCs. Results were visualized by propidium iodide (PI) and Annexin 
V staining.  
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In manuscript II, subtractive hybridization determined that the gene that was most 
induced by HE4 in peripheral blood mononuclear cells (PBMCs) was MKP-3, which 
encodes for the protein DUSP6. Flow cytometry allowed for identification of specific 
immune cell populations within the PBMCs that best characterize this relationship. 
Flow cytometry and western blot examined levels of ERK activation when cells were 
treated with recombinant HE4 and a small molecule DUSP6 inhibitor within specific 
immune cell populations. Cells were treated with recombinant HE4 alone and in 
combination with DUSP6 inhibition, and the following assessments were made: cell 
viability, cell proliferation using Ki67 staining, and apoptosis by flow cytometry 
detection of cells double positive for PI and annexin V. To verify effects the small 
molecule inhibitor on DUSP6, cell viability, proliferation, and apoptosis experiments 
were repeated in a co-culture devoid of the previously identified immune populations 
responsible for upregulation of DUSP6 via HE4.  
In manuscript III, the relationship between HE4 and DUSP6 was further elucidated in 
ovarian cancer cells. To better define DUSP6’s role in EOC, immunohistochemistry 
was performed to determine that levels of DUSP6 expression in patient tissue. Cell 
viability of ovarian cancer cells was assessed following treatment with a small 
molecule DUSP6 inhibitor alone and in combination with platinum-based 
chemotherapeutics to determine synergistic effects. qPCR was used to determine how 
DUSP6 inhibition alone and in combination with carboplatin or paclitaxel alters 
expression of extracellular signal-regulated protein kinases (p-ERK) response genes. 
HE4 and DUSP6 small interfering (si)RNA were employed to determine how 
decreases of either factor affects the other DUSP6 gene and protein levels were 
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assessed in HE4 overexpressing clones using qPCR and western blot.  
In manuscript IV, Septin-2, a protein previously identified as strongly interacting with 
HE4, was characterized in ovarian cancer for the first time. Immunohistochemistry 
was employed to determine Septin-2 expression in EOC tissue. Two stable shRNA 
knockout Septin-2 ovarian cell lines were developed and proliferation of the control 
and knockout cell lines were compared by cell counting. Verification of the 
knockdown was confirmed by quantitative polymerase chain reaction (qPCR) and 
western blot. Finally, proteomics was utilized to determine global changes in protein 
levels in the stable Septin-2 knockout cells. Gene ontology pathway analysis was also 
performed to determine cellular proteins most affected by Septin-2 in EOC. 
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2.1 Abstract  
Human epididymis protein 4 (HE4) is an important clinical biomarker used for the 
detection of epithelial ovarian cancer (EOC). While much is known about the 
predictive power of HE4 clinically, less has been reported regarding its molecular role 
in the progression of EOC. A deeper understanding of HE4’s mechanistic functions 
may help contribute to the development of novel targeted therapies. Thus far, it has 
been difficult to recommend HE4 as a therapeutic target owing to the fact that its role 
in the progression of EOC has not been extensively evaluated. This review 
summarizes what is collectively known about HE4 signaling and how it functions to 
promote tumorigenesis, chemoresistance, and metastasis in EOC, with the goal of 
providing valuable insights that will have the potential to aide in the development of 
new HE4-targeted therapies. 
2.2 Introduction 
Approximately 22,280 new cases of epithelial ovarian cancer (EOC) are diagnosed 
each year, resulting in 14,240 deaths annually in the United States (1). The 5-year 
survival rate for stage III ovarian cancer is only 39% (1). These dire statistics are due 
to the fact that the disease is frequently detected at an advanced stage, which 
drastically impacts overall patient survival. Initially, many patients respond well to 
first-line therapy that includes cytoreduction surgery and platinum-based treatment. 
However, many patients experience a chemoresistant recurrence within the first 2 
years following treatment (2). Therefore, there is an urgent need for tools to aid in the 
early diagnosis of ovarian cancer when the disease is fundamentally curable, as well as  
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improved treatment options for later stage disease. 
Human epididymis protein 4 (HE4) is a secretory protein that is member of the whey 
acidic protein domain family, bearing a conserved motif found in a number a protease 
inhibitors (3). HE4 was initially suggested to be involved in the innate immune 
defense of multiple epithelia and has also been found to function in epithelial host 
defense (4). In ovarian tissue, HE4 is highly overexpressed in EOC compared normal 
tissue (5, 6). Clinically, HE4 has been identified as a novel therapeutic biomarker for 
EOC and has also proven useful in detection of recurrent disease (7) Serum HE4 level 
predicts EOC with equal sensitivity to the established biomarker CA125 and is less 
likely to be elevated in benign disease (5). A multicenter study led by our institution 
established the FDA-approved Risk of Ovarian Malignancy Algorithm (ROMA), 
which combines menopausal status and serum levels of both HE4 and CA125 to detect 
and monitor EOC. ROMA demonstrates improved sensitivity and specificity over the 
Risk of Malignancy Index that uses CA125 alone as a serum based biomarker (6). 
Recently, it has been reported that HE4 can be detected in EOC patient urine, 
indicating the possibility that it may be utilized as a non-invasive biomarker (8). 
While HE4 has been well studied in the clinical setting, less is known regarding its 
specific molecular and biological roles in EOC. Several studies have investigated its 
effect on gene expression in EOC cells, as well as on events associated with 
aggressive disease. This review will summarize HE4’s effect on cell proliferation and 
tumor growth; invasion, migration, and adhesion; chemoresistance; and steroid 
biosynthesis (Figure 1). Each section will detail associated pathways and factors that 
are reported to be involved in these HE4-mediated effects, with the goal of revealing 
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common themes in signaling pathways affected by HE4 and exposing gaps in our 
knowledge of HE4 molecular and biological functions. 
2.3 Review of Literature  
Cell Proliferation and Tumor Growth 
Within the past 5 years, a handful of in vitro and in vivo studies have begun to 
examine HE4’s role in proliferation and tumor growth in EOC. A study by Wang et al. 
examined the role of HE4 in cell proliferation and found that cells treated with 
recombinant HE4 formed a statistically greater number of colonies compared with 
control treated cells (9). Furthermore, cells stimulated with recombinant HE4 
exhibited greater cell viability compared with respective controls. In another study by 
Zhu et al. (10), proliferation rate in two different HE4-overexpressing cell lines was 
significantly higher than in the control cells. Likewise, Zhu et al. (11) and Lee et al. 
(12) determined that when HE4 was ablated via shRNA, cell proliferation decreased 
accordingly. Kong et al. report conflicting results, stating that HE4 inhibits 
proliferation in ovarian cells (13); however, no other studies support these claims, 
necessitating further explanation to understand the implications of their results. 
Several in vitro studies suggest that HE4 promotes proliferation through its 
involvement in cell cycle regulation (11). Silencing of HE4 causes G0/G1 cell cycle 
arrest and blocks the transition from the G1 to the S phase of the cell cycle. 
Conversely, when cells are stimulated with recombinant HE4, the number of cells in 
the G2/M phase is increased, while the number of cells in the G0/G1 phase is reduced 
(9). These results indicate that HE4 may mediate the cell cycle by promoting the 
G0/G1 transition. In addition, in vivo tumorigenicity studies using HE4 knockdown 
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clones revealed a marked inhibition in the growth of ovarian tumors in nude mice (14), 
while injection of HE4-overexpressing cells led to more aggressive tumor growth and 
an overall higher tumor volume compared with controls (10, 15). Taken together, 
results from numerous in vitro and in vivo studies provide compelling evidence that 
HE4 plays a role in cell proliferation and the promotion of tumorigenesis. A full list of 
factors associated with HE4-mediated cell proliferation and tumor growth can be 
found in Table 1A and is outlined in greater detail below. 
 
Associated Pathways and Factors-Cell Proliferation and Tumor Growth  
Human epididymis protein 4 has been connected to several oncogenic signaling 
cascades that play key roles in ovarian cancer progression, including the PI3K/AKT 
pathway, HIF1α, and ERK/mitogen-activated protein kinase (MAPK) signaling. 
Evidence of HE4’s effect on activation of each of these pathways is discussed below. 
 
Protein Kinase B Signaling 
AKT has been established as a strong promoter of tumorigenesis, and the PI3K/AKT 
pathway is one of the most commonly hyperactivated pathways in many types of 
human cancers (16). Its diverse signaling regulates proliferation, growth, survival, 
motility, angiogenesis, and glucose metabolism (17). HE4-overexpressing OVCAR3 
ovarian cancer cells were found to have a marked increase in activation of protein 
kinase B (AKT) compared with control cells, while HE4 knockdown in OVCAR3 
cells reduced AKT activation (12). Moreover, it was found that HE4-overexpressing 
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SKOV3 clones had naturally higher gene levels of AKT3 compared with the null-
vector control (18), bolstering the claim that HE4 affects the PI3K/AKT pathway. 
 
Hypoxia-Inducible Factor-1 Alpha (HIF1α) 
Adaptation of malignant cells to hypoxic conditions is a key step in the promotion of 
tumorigenesis and angiogenesis (19–21), a process that is regulated by the 
transcription factor HIF1α. Co-immunoprecipitation revealed an interaction between 
HIF1α and HE4 in HE4-overexpressing SKOV3 xenografts. There was also strong 
colocalization of HE4 and HIF1α in SKOV3 ovarian xenograft tissue. In addition, 
when SKOV3 cells were treated with HIF1α siRNA or 2-methoxyestradiol (a HIF1α 
inhibitor), there was a marked decrease in HE4 protein levels (15). It is important to 
note that 2-methoxyestradiol is not a specific HIF1α inhibitor as it primarily causes the 
depolymerization of microtubules, which in turn prevents HIF1α expression (22). 
Thus, the specificity of the effect of HIF1α inhibition on HE4 levels may require 
further investigation. Although the exact mechanism and significance of the HE4-
HIF1α interaction is not understood, this evidence suggests that HE4 could play a role 
in regulating HIF1α functions in angiogenesis. 
 
MAPK Signaling 
The MAPK pathway is composed of a family of conserved kinases that mediate 
essential cellular processes such as migration, growth, proliferation, differentiation, 
and apoptosis (23). The extracellular signal-regulated kinase (ERK) pathway is the 
best characterized of all MAPK pathways and is deregulated in approximately one-
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third of all cancers. Several studies have shown activation of ERK in response to HE4 
treatment or overexpression, or suppression of ERK phosphorylation in response to 
HE4 knockdown (11,12,18). Using microarray analysis, Zhu et al. determined that 
seven genes involved in the MAPK pathway (CHUK, GADD45A, IL1A, RPS6KA1, 
HSPA1B, DUSP1, and JUND) were differentially regulated in response to HE4 
overexpression in ES-2 cells (10). 
Activation of the MAPK/ERK pathway occurs through EGF binding of its membrane 
bound receptor, EGFR (24). Using co-immunoprecipitation studies in SKOV3 cells, 
Moore et al. found that HE4 interacts with EGFR, with a greater degree of 
immunoprecipitation seen in HE4-overexpressing clones than wild-type cells (15). 
Furthermore, ovarian xenograft tissue showed colocalization of HE4 and EGFR. In 
addition, when SKOV3 and OVCAR8 cells were stimulated with growth factors EGF, 
VEGF, and Insulin, nuclear localization of HE4 was significantly increased. Finally, 
when EGF was repressed by the small molecule inhibitor Iressa, relative intensity of 
HE4 staining was decreased in ovarian cancer cell lines. Collectively, these results 
provide several layers of evidence that HE4 is tied to growth factor signaling and the 
MAPK/ERK pathway, although further research is needed to elucidate the precise 
mechanisms involved. 
 
HE4’s Role in Proliferation in Other Cancers 
Human epididymis protein 4 has been investigated as a putative biomarker in 
endometrial (25–39), lung (40–52), breast (53, 54), pancreatic (55, 56), and gastric 
cancer (57). While the majority of these studies examine the value of HE4 as a clinical 
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biomarker for detecting and monitoring disease, one study investigated the molecular 
mechanisms of HE4 in pancreatic and endometrial cancer. Lu et al. stimulated both 
pancreatic and endometrial cancer cell lines with recombinant HE4 and found that cell 
viability, cell growth, and DNA synthesis was increased prominently in both cancer 
types (56). They also report that HE4 upregulates gene expression of proliferating cell 
nuclear antigen (PCNA) and downregulates p21 in both cancer cell lines in a dose 
dependent manner. PCNA, which is expressed in the late G1/S phase of the cell cycle, 
is required for DNA repair, replication, cell proliferation, and cell cycle progression 
(58), while p21 is an important effector of tumor suppressor pathways by promoting 
cell cycle arrest. Specifically, p21 is able to facilitate p53-dependent G1 growth arrest 
(59). Therefore, results from this study highlight HE4’s role in proliferation in both 
pancreatic and endometrial cancer and lend support to similar evidence from studies 
published on EOC. 
 
Invasion, Migration, and Adhesion 
Several studies have associated HE4 with metastatic properties, including invasion, 
migration, and adhesion of ovarian cancer cells. Lu et al. found that adhesion to a 
fibronectin substrate was twofold greater in SKOV3 cells overexpressing HE4 than in 
mock cells. In addition, a transwell migration assay demonstrated that the HE4-
overexpressing clones had a 1.8-fold greater migration capacity than mock transfected 
cells. By contrast, immunofluorescence analysis showed that HE4 knockout clones 
displayed inhibited cell-spreading ability in a statistically significant fashion compared 
with respective controls. Furthermore, cell invasion, proliferation, and migration were 
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significantly decreased in these clones (14). In agreement with this study, Ribeiro et 
al. also found that OVCAR8 ovarian cells treated with recombinant HE4 exhibited 
2.07-fold greater invasion capacity and 1.29-fold greater adhesion to a fibronectin 
matrix compared with untreated controls. Interestingly, there was no change in 
adhesion to collagen I, IV, laminin I, and fibrinogen matrices, suggesting that HE4 has 
a specific effect on fibronectin adhesion. Haptotaxis toward a fibronectin substrate 
also was increased in the ovarian cancer cells treated with recombinant HE4 by 1.72-
fold (60). 
Zhu et al. used wound healing and transwell invasion assays to show that HE4-
overexpressing ES-2 and CaOV3 cells possess enhanced cell migration and invasion 
capacities. In addition, in vivo tail vein injection of HE4-overexpressing ES-2 cells 
into nude mice resulted in significantly more metastatic lung nodules than mock 
transfected cells (10). Using the same ovarian cancer cell lines, Zhuang et al. report 
the importance of HE4 interaction with annexin II (ANXA2) to promote invasion and 
migration in vitro and metastasis in vivo (61). Finally, Zou et al. found that 
knockdown of HE4 in SKOV3.ip1 cells inhibited migration and invasion (62). Taken 
together, these studies strongly suggest that HE4 plays a prominent role in the 
promotion of ovarian cancer metastasis. A full list of factors associated with HE4-
mediated invasion, migration, and adhesion can be found in Table 1B and is outlined 
in greater detail below. 
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Associated Pathways and Factors—Invasion, Migration, and Adhesion 
Human epididymis protein 4 appears to interact with numerous molecular pathways 
that promote metastasis in ovarian cancer. However, it is still not entirely known how 
HE4 affects signaling pathways and gene expression signatures to promote invasion, 
migration, and adhesion of ovarian cancer cells. Following is a summary of HE4-
mediated molecular pathways that are involved in metastatic events in EOC. 
 
Matrix Metalloproteinases (MMPs) 
Human epididymis protein 4 has been associated with MMPs MMP-9 and MMP-2, 
and Cathepsin B. MMPs are a family of zinc-dependent endopeptidases that are vital 
for the remodeling of the extracellular matrix (63). They are expressed in almost all 
types of cancers and are responsible for stimulating angiogenesis, tumor growth, and 
metastasis (64, 65). Cathepsin B is a lysosomal cysteine protease that has been linked 
to cancer progression (66), specifically in signaling pathways related to angiogenesis 
(67). In addition, it can promote MMP activity by degrading MMP inhibitors (68). 
Interestingly, silencing of HE4 in ovarian cancer cells led to a decrease in protein 
levels of MMP-9, MMP-2, and Cathepsin B, suggesting these factors may be involved 
in HE4-mediated tumor promoting effects (11). 
 
 
Interleukin-1 alpha (ILIA) 
 
Interleukin-1 alpha is a pro-inflammatory cytokine that is involved in angiogenesis 
and metastasis. ILIA can directly stimulate the synthesis of VEGF (69) and 
fibroblastic pro matrix metallic proteinase I (70, 71). IL1A causes resistance to EGFR 
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inhibitors in both colon and head and neck cancers (72, 73). IL1A was also found to 
be differentially expressed in three separate microarray studies involving HE4. In two 
microarrays, IL1A levels positively associated with HE4 levels (10, 74), while in one 
study their levels were inversely associated (18). While there may be some ambiguity 
as to how HE4 and IL1A are mechanistically linked, the consistent connection 
between IL1A with HE4 merits further investigation. 
 
Extracellular Matrix Proteins 
Integrins are a family of transmembrane proteins that are vital to ECM adhesion and 
play important roles in wound healing as well as the pathogenesis of cancer (75–77). 
Integrin β5 (ITGβ5) gene expression was differentially regulated by HE4 in ES-2 and 
CaOV3 cells, which was confirmed by positive correlation of ITGB5 and HE4 
staining in paraffin embedded ovarian tissue samples (10). This finding suggests that 
integrin signaling is one mechanism by which HE4 can promote increased adhesion of 
ovarian cancer cells. However, further research is needed to clarify the mechanisms 
involved. 
In addition to ITGβ5, three other genes related to ECM modeling—syndecan 1 
(SDC1), collagen type 1 alpha 1 (COL1A1), and dystroglycan 1 (DAG1)—were more 
highly expressed in cells overexpressing HE4 and were downregulated in cells with 
HE4 knockdown (10). SDC1, also known as CD138, is an essential cell surface 
adhesion molecule that is responsible for maintaining cell morphology and 
interactions within the surrounding microenvironment (78). Loss of SCD1 in cancer 
cells is associated with reduced ECM adhesion and enhanced invasion and cell 
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motility (79). Another ECM gene found to be affected by HE4 expression levels, 
COL1A1, is a crucial component of the ECM as it supports cartilage, bone, and tendon 
tissues in the body and also functions to maintain the rigidity and elasticity of tissues 
(80, 81). COL1A1 plays an important role in cancer, since tumor cells that express 
COL1A1 are able to dissociate from their surrounding stromal components, which is 
essential for tumor growth (81). The final ECM gene found to be affected by HE4 is 
DAG1, which is a cell adhesion molecule that plays a key role basement membrane 
assembly (82), muscle integrity (83), and the maintenance of basolateral cell adhesion 
in numerous epithelial tissues (84). Loss of DAG1 is associated with cancer 
progression (85). Taken together, these results show that HE4 is strongly 
interconnected with ECM related proteins, specifically those involved in the ITGβ5 
signaling pathway. 
Our lab has also determined that HE4 regulates several components of the 
extracellular matrix (60). We performed microarray analyses comparing untreated 
OVCAR8 wild-type cells to recombinant HE4 treated cells, and OVCAR8 cells 
overexpressing HE4 to null-vector control cells. Serpin peptidase inhibitor, member 2 
(SERPINB2), gremlin 1 (GREM1), laminin-β3 (LAMB3), laminin-γ2 (LAMC2), 
fibroblast growth factor 5 (FGF5), and tenascin C (TNC) were all found to be 
significantly upregulated upon treatment with recombinant HE4. These genes encode 
for extracellular matrix proteins that promote cell migration and adhesion (60). 
Specifically, we found that HE4 upregulates LAMC2 and LAMB3 proteins in a time-
dependent manner, and this increase of both factors in turn leads to an increase in 
laminin-332 levels (60). Laminin-332, a heterotrimer composed of LAMC2, LAMB3, 
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and LAMA2, is an important component of the basement membrane in epithelial 
tissue. Abnormal increases in its levels have been shown to promote increased 
invasion in cancers (86). Further evidence suggested involvement of the FAK pathway 
in these events. In addition, activation of matriptase, a serine protease responsible for 
cleaving laminin-332 in its β chain and regulating its effects on metastatic properties, 
increased upon in vitro exposure to recombinant HE4 (60). This study provides 
compelling evidence that HE4 is involved in basement membrane invasion and 
adhesion. 
 
Lewis y Antigen 
Human epididymis protein 4 undergoes glycosylation before it is secreted by ovarian 
cells (87), prompting Zhuang et al. to examine the relationship between HE4 
glycosylation status and metastatic properties. Lewis y antigen is a glycosyl antigen 
that is overexpressed in ovarian cancer and has been associated with chemoresistance 
and poor prognosis (88–97). They determined that Lewis y antigen was present in 
HE4 from benign and malignant ovarian tissues, in vitro cancer cells, and culture 
medium. HE4 from ovarian cancer samples contained higher levels of Lewis y antigen 
than HE4 from benign tissues, and their expression co-localized in ovarian cancer 
tissue (98). Furthermore, when Lewis y antigen was over expressed, it promoted HE4-
mediated invasion and metastasis in ovarian cancer cell lines. Conversely, when Lewis 
y antigen was blocked, the invasive and metastatic properties of HE4 were 
significantly decreased (99). Interestingly, overexpression of Lewis y antigen 
increased tyrosine phosphorylation of EGFR and HER/neu, which promoted cell 
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proliferation through the PI3K/Akt and Raf/MEK/MAPK pathways (100). Thus, it 
appears that Lewis y antigen and HE4 affect similar signaling pathways that promote 
tumor growth and malignancy (101). Taken together, these results show that Lewis y 
antigen could be a potential therapeutic target to decrease HE4 function in the 
treatment of EOC. 
 
Heparin Cofactor II (HCII) 
SERPIND1 encodes for the protein HCII, which is a serum glycoprotein and protease 
inhibitor (102). A study in non-small cell lung cancer (NSCLC) showed that HCII 
promotes cell motility, invasion, and filopodium dynamics through the PI3K/AKT 
pathway. High HCII expression in NSCLC tissue correlated to an increased recurrence 
rate and shorter overall survival (103). Furthermore, its levels were upregulated in 
metastatic brain cell lines compared with non-metastatic parental lines, suggesting an 
involvement of SERPIND1 in metastatic functions (104). Results from a microarray 
study by Zhu et al. showed that SERPIND1 was upregulated in HE4-overexpressing 
cells and conversely downregulated in HE4 knockdown cells. These results were 
validated via qPCR and immunohistochemistry. In addition, they found that 37/50 
ovarian cancer samples showed positive expression of both SERPIND1 and HE4, and 
Spearman correlation analysis confirmed that HE4 and SERPIND1 were positively 
correlated. Finally, Kaplan–Meier analysis revealed that patients with high levels of 
HE4 and SERPIND1 had a worse prognosis (74). While these data strongly suggest a 
connection between HE4 and SERPIND1, which may be related to their roles in 
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promoting ovarian cancer metastasis, further study of the association between these 
two proteins is required. 
 
 
Annexin II 
 
Annexin II is a calcium-dependent, phospholipid-binding protein that is overexpressed 
in a variety of cancers and is involved in angiogenesis, proliferation, apoptosis, cell 
migration, invasion, and adhesion (105). High levels of Annexin II activate MAPK 
signaling, which in turn promotes tumor proliferation (106), invasion (107), and 
metastasis (108). Zhuang et al. employed mass spectrometry and co-
immunoprecipitation to identify Annexin II (ANXA2) as a strong HE4 interacting 
partner (61). This binding promoted invasion and metastasis in ES-2 and CaOV3 
ovarian cancer cells. HE4 and ANXA2 gene expression levels were found to be co-
dependent, and examination of EOC tissue revealed that both HE4 and Annexin II 
levels were increased in malignant phenotypes compared with benign and normal 
ovarian tissues. Both proteins were also more highly expressed in tissues from patients 
with lymph node metastases than those without. Downregulation of HE4 was found to 
decrease expression of MKNK2 (MAP kinase-interacting serine/threonine-protein 
kinase 2) and LAMB2 (laminin, beta-2), two factors associated with MAPK and focal 
adhesion signaling pathways. When HE4 protein was supplemented, this effect was 
reversed. Collectively, these results show that HE4 interaction with Annexin II to 
activate MAPK and focal adhesion signaling is one mechanism by which HE4 may 
promote ovarian cancer metastasis. 
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Chemoresistance 
Several studies show that HE4 is associated with chemoresistance clinically. The 
addition of HE4 serum levels in the ROMA score better predicts platinum resistance in 
patients than CA125 alone (15). Angioli et al. found that HE4 was able to predict 
chemotherapy response in EOC patients undergoing first-line therapy (109). In 
addition, higher levels of serum HE4 are reported in women who are resistant to first-
line chemotherapy (110). Finally, higher HE4 levels inversely correlate with clinical 
outcome (111), optimal cytoreduction (112), progression free survival (113), and 
overall survival (15, 113). While the mechanism underlying HE4’s contribution to 
chemoresistance has not been established fully, a few studies have begun to delineate 
HE4’s role in this process. A full list of factors associated with HE4-mediated 
chemoresistance can be found in Table 1C and is outlined in detail below. 
 
Associated Pathways and Factors—Chemoresistance 
Antiapoptotic Gene Expression 
A study performed in our lab by Ribeiro et al. determined that HE4 overexpression 
promotes collateral chemoresistance to both cisplatin and paclitaxel in SKOV3 and 
OVCAR8 cells (18). Conversely, CRISPR/Cas9 mediated knockdown of HE4 in 
SKOV3 cells overexpressing HE4 partially reversed their chemoresistance. 
Microarray analysis revealed suppression of cisplatin-induced early growth response 1 
(EGR1) gene expression in HE4-overexpressing SKOV3 cells compared with null 
vector-transfected cells (18). EGR1 is a transcription factor that regulates apoptosis, 
proliferation, and differentiation through regulating expression of genes such as p53, 
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BCL2, PTEN, IGF2, PDGF, VEGF, TGFB1, and TNF (114, 115). EGR1 expression is 
influenced by MAPK signaling, including phospho-ERK and phospho-p38 (115). 
Ribeiro et al. found that p38 was strongly activated in SKOV3 null vector-transfected 
cells treated with cisplatin, while its activation was suppressed in HE4-overexpressing 
clones (18), suggesting that HE4-mediated chemoresistance may involve MAPK 
signaling. 
Similarly, a study by Wang et al. showed that HE4 represses carboplatin-induced 
apoptosis in vitro. Recombinant HE4 caused an increase in expression of antiapoptotic 
protein B-cell lymphoma 2 (BCL-2) and a decrease in expression of pro-apoptotic Bax 
(Bcl-2 associated X protein) in SKOV3 cells treated with carboplatin (9). This 
decrease in the Bax/Bcl-2 ratio, in addition to the suppression of EGR1 when HE4 is 
overexpressed, may contribute to the overall decrease in pro-apoptotic factors that 
leads to chemoresistance in EOC. 
 
Microtubule Stabilization 
Microtubule-associated protein tau, which has been associated with paclitaxel 
resistance in ovarian (116), breast (117), and gastric cancer (118), was upregulated in 
SKOV3 cells overexpressing HE4 compared with null-vector cells (18). In addition, 
HE4-overexpressing cells were found to express significantly higher levels of SEPT3 
(Septin 3) mRNA compared with null-vector controls (18). Septins are a family of 
conserved GTP binding proteins that are associated with microtubules and actin 
filaments and have an important role in cytoskeletal organization (119). Furthermore, 
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recombinant HE4 treatment of SKOV3 cells increased β-tubulin levels, indicating that 
HE4 might promote microtubule stability, leading to paclitaxel resistance. 
 
Kinase Signaling Pathways 
Human epididymis protein 4 knockdown has also been shown to lead to a reduction in 
cell growth and the resensitization of ovarian cancer cells to both cisplatin and 
paclitaxel (12). Lee et al. found that this effect was due to corresponding decreases of 
ERK and AKT in HE4 knockouts. Activation of these pathways suppresses apoptotic 
signaling in tumors, suggesting that HE4’s regulation of these pathways may be an 
important mechanism of chemoresistance (120). 
 
Steroid Biosynthesis 
Evidence suggests an association between sex steroids and EOC pathogenesis, which 
is explained by processes that take place during the menstrual cycle. The ovarian 
surface epithelium (OSE) plays a critical role in ovulation and postovulatory wound 
repair. During the menstrual cycle, the OSE proliferates during the pro-estrus/estrus 
transition. After, ovulation the proliferation rate decreases (121). It is hypothesized 
that when the OSE is repeatedly exposed to high doses of luteinizing hormone and 
follicle stimulating hormone during the menstrual cycle, this can promote cell 
proliferation and increase the likelihood of tumor growth over time (121). 
Furthermore, epidemiological data have suggested that ovarian cancer progression, 
pathogenesis, and etiology are highly dependent on the activity of estrogens (121), and 
numerous experimental studies have demonstrated the promotive effect of estrogens 
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on ovarian tumors in mice and human EOC cell lines (122). However, activation of 
diverse oncogenic pathways in EOC may lead to the eventual downregulation of ERα 
levels and the overall decrease in ERα related signaling in ovarian cancers, rendering 
them resistant to anti-estrogen therapies (122). Some evidence exists that HE4 may be 
involved in this process by regulating steroid signaling in EOC. A full list of factors 
associated with HE4-mediated steroid biosynthesis can be found in Table 1D and is 
outlined in detail below. 
 
Steroid Biosynthesis Gene Expression 
Two separate microarray pathway analyses identified steroid biosynthesis as a 
pathway affected by HE4 (10, 74). Important genes that were differentially expressed 
between HE4-overexpressing and HE4 knockdown cell lines were Forkhead box 
protein A2 (FOXA2) (74), squalene monooygenase (SQLE), 7-dehydrocholesterol 
reductase (DHCR7), 24-dehydrocholesterol (DHCR24), and sterol-4-alpha-
carboxylate-3-dehydrogenase (NSDHL) (10). FOXA2, a transcription factor required 
for normal metabolism (123), promotes cell proliferation, maintains cancer stem cells, 
and is associated with a higher rate of relapse in triple-negative breast cancer (124). 
Another gene differentially regulated by HE4, SQLE, is an enzyme required in the 
later stages of cholesterol synthesis (125). Out of 22 cancer types, SQLE copy 
number-driven gene expression was highest in breast, ovarian and colorectal cancer 
(125). Also affected by HE4 levels was DHCR7, one of the terminal enzymes 
involved in the production of cholesterol from 7-dehydrocholesterol (7DHC). DHCR7 
was found to be an important regulatory determinate between cholesterol and vitamin 
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synthesis, as cholesterol is able to accelerate the proteasomal degradation of DHCR7, 
which can result in the accumulation of 7DHC and an increased production of vitamin 
D (126). DHCR24, which was also affected by modulation of HE4 levels, is another 
enzyme in the cholesterol biosynthesis pathway (127). It interacts physically and 
functionally with DHCR7 (128) and has a number of different cellular functions 
including anti-inflammatory and antiapoptotic functions, as well as regulation of 
oxidative stress and cell differentiation (129). DHCR24 has also been proposed to be 
involved in tumor progression, as its deregulation has been linked to prostate, ovarian, 
and urothelial carcinomas (127). 
Finally, NSDHL is also involved in cholesterol biosynthesis and produces metabolites 
that are essential in the conversion of squalene to cholesterol (130). Interestingly, 
NSLD1 was found to have a role in the control of signaling, vesicular trafficking, and 
degradation of EGFR and its dimerization partners ERBB2 and ERBB3. A study by 
Sukhanova et al. showed that NSLD1 knockout in vivo leads to a reduction in EGFR 
activation (131). The results from these microarrays show that modulating HE4 levels 
results in differential expression of several genes involved in steroid biosynthesis—
especially cholesterol—suggesting that HE4 may affect tumor metabolism and 
ultimately contribute to tumorigenesis. 
 
Estrogen Signaling 
In support of the above described pathway analyses, two other studies have shown that 
HE4 interacts with steroid signaling, specifically estrogen signaling. Lokich et al. 
showed that ERα expression was reduced in HE4-overexpressing SKOV3 cells, 
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resulting in increased resistance to tamoxifen and fulvestrant compared with wild-type 
cells (132). 5-Methylcytosine (5-MC), a methylated form of the DNA base cytosine, is 
one of the most prominently identified epigenetic modifications, and can cause 
suppression of ERα gene expression. Deregulation of DNA methylation can result in 
abnormal gene expression and tumorigenesis (133, 134). Lokich et al. found that 5-
MC was readily detected in SKOV3 wild-type and null-vector cells but not in HE4-
overexpressing clones, suggesting that HE4 overexpression may have an effect on 
epigenetic modifications (132). However, methylation of the ERα gene was not 
specifically examined in this study. It is unclear whether HE4 overexpression would 
promote increased methylation at the ERα promoter region (even with the presence of 
global demethylation), which would be expected given the reported suppression of 
ERα in this study. 
Interestingly, Chen et al. reported that when HO8910 ovarian cancer cells were 
stimulated with estradiol (E2), there was an increase in the expression of HE4 at the 
mRNA and protein level. This effect was not observed in estrogen-insensitive SKOV3 
cells; however, when HE4 was knocked down in SKOV3 cells, their proliferative 
response to estrogen was restored (135). Collectively with the results shown by Lokich 
et al, this study suggests that HE4 works to suppress estrogen signaling in ovarian 
cancer cells, which can contribute to resistance to anti-estrogen therapies. Conversely, 
it appears that estradiol promotes HE4 expression in estrogen-responsive cells, which 
could indicate a role for HE4 in the initial tumor promoting effects of estrogen. 
Further clarification of the effect of HE4 on estrogen signaling may be useful in 
improving implementation of anti-estrogen based therapies. 
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2.4 Conclusion 
Ovarian cancer is an extremely deadly disease owing to the fact that patients are 
typically diagnosed at a late stage. Initially, patients respond well to frontline platinum 
therapy; however, a majority of tumors recur, and the initial chemosensitivity 
eventually gives way to a broad chemoresistance (136). Available detection methods 
have improved in recent years with the discovery of HE4 as a diagnostic and 
prognostic biomarker. However, there has yet to be a breakthrough targeted therapy to 
combat EOC. While PARP inhibitors are used in the maintenance setting for all 
patients, this therapy has most significantly benefited BRCA-positive patients, who 
comprise only 20–25% of patients (137, 138). In addition, inhibitors of immune 
checkpoints, such as programmed death ligand-1 have demonstrated modest benefit in 
clinical trials for ovarian cancer (139). Therefore, there is still a crucial need for novel 
targeted EOC treatments. 
Although HE4 is well established as a clinical biomarker for ovarian cancer, it has 
been largely understudied for its therapeutic targeting potential. However, ongoing 
research continues to support that HE4 is profoundly involved in the pathogenesis of 
EOC. The individual studies mentioned in this review provide evidence that HE4 
promotes EOC progression through pathways associated with cell proliferation, tumor 
growth, metastasis, chemoresistance, and steroid biosynthesis. These pathways, along 
with specific genes that have been shown to be associated with HE4, are summarized 
in Table 1. This compilation of HE4 regulated factors and pathways will serve as a 
starting point for scientists to further elucidate specific mechanisms by which HE4 
ultimately drives tumorigenesis. In addition, a comprehensive summary of clinical, in 
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vivo, and in vitro studies related to each facet of EOC progression and HE4 can be 
seen in Figure 1. This diagram highlights the progress that has been made to establish 
HE4 as an attractive therapeutic target, while simultaneously denoting areas of 
research that are still lacking. The results discussed here suggest that inhibition of 
HE4 via a neutralizing antibody or small molecule inhibitor could provide viable 
treatment options for patients in dire need of more effective therapies. 
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Figure 2.1 Graphical Representation of clinical, in vivo and in vitro studies completed 
relating to HE4 and EOC. 
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Table 2.1 Summary of factors associated with HE4 in EOC  
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I.1 Abstract  
Ovarian tumors are known to suppress immunosurveillance and promote immune 
escape. Here, we examine the role of the secretory glycoprotein HE4 in ovarian cancer 
immune evasion. Through modified subtractive hybridization analyses of human 
peripheral blood mononuclear cells (PBMCs), we have characterized gene targets of 
HE4 and established a preliminary mechanism of HE4-mediated immune failure in 
ovarian tumors. Upon exposure of PBMCs to recombinant human HE4 in vitro, 
osteopontin (OPN) emerged as the most suppressed gene, while DUSP6 was the most 
upregulated gene. SKOV3, a human ovarian carcinoma cell line, exhibited enhanced 
proliferation in conditioned media from HE4-exposed PBMCs, and this effect was 
attenuated by the addition of recombinant OPN or OPN-inducible cytokines (IL-12 
and IFN-). Additionally, upon co-culture with PBMCs, HE4-silenced SKOV3 cells 
were more susceptible to cytotoxic cell death.  The relationship between HE4 and 
OPN was further reinforced through analysis of serous ovarian cancer patient samples. 
In these biopsy specimens, the number of OPN+ T cells correlates positively with 
progression free survival (PFS) and inversely with serum HE4 level. Taken together, 
these findings show that HE4 enhances ovarian cancer tumorigenesis by 
compromising OPN-mediated T cell activation.  
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I.2 Introduction 
Human epididymis protein 4 (HE4) is a member of the whey acidic domain family of 
proteins (WAP), which are generally regarded as protease inhibitors (1-3). HE4 was 
first identified in the male reproductive tract but has since been found in select other 
tissues, such as the kidney, female reproductive tract, breast, and lungs (4,5). In 
addition, it is highly overexpressed in several human malignancies, including ovarian 
and endometrial cancer (5-8). HE4’s role in normal and malignant tissue is still 
unclear; however, as a known negative prognostic factor in women with epithelial 
ovarian cancer, its serum levels correlate with chemoresistance and reduced survival 
(9-11). Our previous work with HE4 has led to the development of a USFDA 
approved biomarker tool for evaluation of pelvic masses, coined the Risk of Ovarian 
Malignancy Algorithm (ROMA) (12-15). The ROMA score incorporates HE4, CA-
125, and menopausal status into a calculation to estimate ovarian cancer risk. As a 
biomarker, HE4 detection and monitoring is already improving patient care. However, 
it is imperative that we learn more about its function in order to better understand 
ovarian tumorigenesis and ultimately develop effective therapies for this fatal cancer. 
In this present study, we begin to elucidate HE4’s role in the interplay between tumor 
cells and the immune system. We generated cDNA-subtracted libraries of HE4 treated 
peripheral blood mononuclear cells (PBMCs) and employed a modified subtractive 
hybridization method to identify differentially expressed genes. This strategy 
identified osteopontin (OPN) as one of the most prominently suppressed targets in 
PBMCs following HE4 treatment. OPN is a secretory glycosylated phosphoprotein 
encoded by the gene SPP1. OPN contains an arginine-glycine-aspartate (RGD) 
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sequence that—via interactions with integrin family members or CD44—triggers 
downstream signaling events and relays early cell-mediated immune responses (16-
18). We observed that HE4-induced OPN suppression mitigated the cytotoxicity of 
PBMCs against cultured human ovarian cancer cells in vitro. Further, the expression 
levels of OPN in stromal infiltrating T cells in biopsy samples from serous ovarian 
cancer patients showed direct association with patient progression free survival (PFS). 
Together, our data demonstrates that HE4 inhibits the immune function of PBMCs, 
most prominently T cells, via suppression of OPN production.  
 
I.3 Materials and methods 
Subtractive hybridization and TA-cloning.  
Primary human PBMCs were obtained under the auspices of Women & Infants 
Hospital IRB approval from a single volunteer. Approximately 5 x 107 of PBMCs 
were obtained from 40 mL of heparinized total blood. The cells were suspended in 5 
mL of serum free RPMI1640 medium (#31800022; Invitrogen, Carlsbad, CA, USA) 
and incubated with or without 0.01 g / mL (approximately 270 pM) of rHE4 
(MBS717359; MyBiosource, San Diego, CA, USA) for 6 hours, and total RNA was 
isolated using TRIzol reagent (Invitrogen). The dose of HE4 (0.01 g / mL, 270 pM) 
was chosen as a comparable concentration to serum levels in patients with various 
types of ovarian tumors (19). Around 300 g of total RNA was isolated in this scale of 
preparation. The RNA was stored at -80 degrees until messenger RNA (mRNA) 
isolation. Blood draws were repeated at a minimum of 7-day intervals until the amount 
of total RNA collected reached 1 mg. Next, mRNA was purified using oligo dT coated 
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magnetic beads (Takara-Clontech, Mountain View, CA, USA). Approximately 10 g 
of mRNA was isolated from the 1 mg of total RNA, from which subtractive cDNA 
libraries were constructed using PCR-SelectTM cDNA Subtraction Kit (Takara-
Clontech, Mountain View, CA, USA), following the manufacturer’s instructions. 
Briefly, the tester and driver cDNAs are synthesized from poly A+ RNA generated 
from control and HE4 treated PBMCs. The tester and driver cDNAs are each digested 
with a restriction enzyme, Rsa I, to yield shorter, blunt-ended molecules. The tester 
cDNA is then subdivided into two portions, and each is ligated with a different cDNA 
adaptor. The ends of the adaptor do not contain a phosphate group, so only one strand 
of each adaptor attaches to the 5' ends of the cDNA. The two adaptors have stretches 
of identical sequence to allow annealing of the PCR primer once the recessed ends 
have been filled in. The differentially expressed genes were identified through two 
steps of hybridizations followed by two steps of PCR. The PCR products of the 
differentially expressed genes were cloned into a pUC19-TA vector. The clones 
containing the inserts were selected by blue/white selection and were amplified by 
colony PCR using M13 primers.  
 
Cell culture 
The human ovarian cancer cell lines SKOV3 and OVCAR8 were obtained from 
ATCC (Manassas, VA, USA). RPMI1640 (#31800022; Invitrogen) and DMEM 
supplemented with 1.0 mM of sodium pyruvate (#31600034; Invitrogen) were used 
for culturing PBMC and SKOV3, respectively. Conditioned media was obtained from 
24-hour PBMC culture with or without 0.01 g / mL (270 pM) of rHE4. Residual 
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rHE4 in the conditioned media was deprived as follows. Five mLs of media was 
incubated with 10 g (100 L) of anti-human HE4 antibody (sc-293473; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) for 1 hour at 4 degrees. Then, 100 L packed 
volume of protein G coated sepharose beads (GE Healthcare Life Science, Pittsburg, 
PA, USA) was added and incubated for 4 hours at 4 degrees. After the incubation, the 
sepharose beads were removed by centrifugation and the supernatants were processed 
through a sterile 0.2 m pore syringe filter. The conditioned media were used without 
any dilution. For the cell-mediated cytotoxicity assay, 2 x 105 target cells (SO or 
shHE4 transfected SKOV3) were seeded in each well of 6-well plates, and then were 
incubated overnight with complete media. The next day, cells were placed in serum 
free media for another overnight incubation to induce quiescence, and then 1 x 107 of 
the effector cells (PBMC) mixed with propidium iodide (Invitrogen) were added to 
each well. Some of the wells contained 5 pg / mL of rIL-12 (219-IL-005; R&D 
Systems, Minneapolis, MN, USA), 20 pg / mL of rIFN- (SRP3058; Sigma-Aldrich, 
St. Louis, MO, USA) or 0.05 g / mL of rHE4 (ab132299; Abcam) in combinations as 
indicated in Figure 4 (lower panel). The ovarian cancer cell lines were 
morphologically normal and kept growing up to 72 hours in serum deprived DMEM. 
In order to avoid unexpected effects of unknown constituents in the serum, all 
experiments were performed under serum free condition. shRNA for human HE4 
(TR318721; Origene, Minneapolis, MN, USA) were transfected into SKOV3 using 
Lipofectamine 2000TM (Invitrogen) following the manufacturer’s instructions. In other 
cases, cells were treated with 20 pg / mL recombinant OPN (ab92964; Abcam) or 0.01 
g / mL rHE4.  
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Quantitative Real-Time PCR  
RNA was isolated from PBMCs of healthy donors using TRIzol (Invitrogen) 
according to the manufacturer’s instructions. cDNA was synthesized using 
SuperScript III reverse transcriptase (Invitrogen). qPCR was performed using Premix 
Ex-TaqTM II (Clontech-Takara) probes for OPN, IL-12B and IFN-. All reactions were 
normalized using GAPDH as an endogenous control. Amplification data were 
analyzed using the  Ct method.  
 
Flow cytometry  
FITC-labeled anti CD3 (HIT3a), CD14 (M5E2), CD19 (HIB19) and CD56 (B159) 
antibodies were obtained from BD Biosciences (Billerica, MA, USA). Alexa Fluoro® 
647-labeled anti OPN antibody (EPR3688) was obtained from Abcam. After staining 
for cell surface markers (CD3, CD14, CD19 and CD56), the cell membrane was 
permeabilized by 0.2 % Triton X-100 and 0.2 % digitonin, and then stained for OPN. 
Flow cytometric analysis was performed with FACSCanto system and FACSDiva 
software (BD Biosciences).  
 
ELISA  
ELISA kits for OPN, IL-12AB, IFN- and HE4 were obtained from R&D Systems. 
The assays were performed following the manufacturer’s instructions. 
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Viability and migration assays  
1 x 103 / well SKOV3 cells were seeded in a 96-well culture plate. After overnight 
incubation with serum free medium, conditioned media was added to the quiescent 
cells that were cultured for 24, 48 and 72 hours. The cell viabilities at each time point 
were evaluated using CellTiter-Blue® (Promega, Madison, WI, USA). Cell migration 
assays were performed using InnoCyteTM Cell Migration Assay (EMD Millipore, 
Taunton, MA, USA). 5 x 104 SKOV3 cells were seeded in the upper chamber of a 96-
well plate with the lower chamber containing the PBMC-conditioned media. 
Migration activities were accessed after incubating the cells for 24 hours in a CO2 
incubator at 37 °C. 
 
Immunohistochemistry 
SKOV3 cells were seeded at 0.5 x 104 / chamber in a 4-chamber slide. After overnight 
incubation with serum free medium, conditioned media was added to the quiescent 
cells and the cells were cultured for 48 hr. The cells were fixed with 2 % 
formaldehyde and permealized by 0.2 % TritonX-100. The slides were then incubated 
with a mouse monoclonal anti-Ki67 antibody (clone B56; PD Pharmingen, Franklin 
Lakes, NJ, USA) overnight at 4°C in a humidified chamber. The slides were then 
incubated with an ALP conjugated anti-mouse IgG (H+L) secondary antibody (Bio-
Rad, Hercules, CA, USA) for 30 minutes at room temperature. Bound antibody was 
detected using the ALP substrate kit (Vector Laboratories, Burlingame, CA, USA) and 
lightly counterstained with veronal acetate buffered 1% methyl green solution, pH 4.0 
(Vector laboratories). PermountTM (Fisher Scientific, Ottawa, Ontario, Canada) was 
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used as the mounting media and sections were cover slipped. The 
immunohistochemical studies were repeated four times on samples prepared from 
different cultures. The proportion of Ki67 positive cells was calculated according to 
the following formula: 100 × (the number of Ki67-positive nuclei/total number of 
nuclei). Each image was analyzed at least four times to obtain an average labeling 
index. 
 
Western blotting 
 Cellular contents of HE4 in SKOV3 cell lines transfected with shRNA against HE4 
were assessed by western blotting. Antibodies against HE4 were obtained from 
Origene (TA326648). Anti-actin antibody (clone 2G2; EMD Millipore) was used for 
detection of the internal loading control. The results were visualized with 
SuperSignal™ West Pico chemiluminescent substrate (ThermoFisher Scientifics) and 
analyzed with the UN-SCAN-IT gel software for Windows (Version 6.1; Silk 
Scientific Inc.). 
 
Confocal immunofluorescent microscopy 
Formalin-fixed, paraffin-embedded tissue sections were cut to a thickness of 4 m. 
For heat-induced epitope retrieval, deparaffinized sections in 0.01 M citrate buffer 
were treated three times at 90 °C for 5 minutes using a microwave oven. After 
blocking with 10% normal horse serum, sections were incubated with rabbit anti-OPN 
antibody (FL-314; Santa Cruz Biotechnology) or mouse anti-CD3 (PS-1; Abcam) 
overnight at 4 °C, washed with PBS and incubated with DyLight 488 goat anti-rabbit 
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IgG (DL1488; Vector Laboratories) or DyLight 594 horse anti-mouse IgG (DL2594; 
Vector Laboratories) secondary antibodies for 1 hour at room temperature in the dark. 
Slides were washed again with PBS and cover-slipped with DAPI-containing 
mounting medium (Vector Laboratories). Confocal images were acquired with a 
Nikon C1si confocal (Nikon Inc. Mellville, NY, USA) using diode lasers 402, 488 and 
561.  Ten fields/sample were randomly selected based on DAPI staining and counts 
were performed for CD3 and OPN using a 40x objective. Counts are expressed as # of 
positive cells/mm2. All donors of the biopsies and the PBMCs provided written 
informed consent. The study was approved by the Women & Infants Hospital ethics 
committee. 
 
Statistics 
Data ware expressed as average ± SEM of at least three independent experiments. An 
unpaired, two-tailed Student t-test was used to determine significance. Multiple 
treatments were analyzed by using one-way ANOVA followed by Ryan’s multiple 
comparison test. Spearman's rank correlation test was used to assess the 
immunofluorescent staining on biopsy specimens. Differences between groups were 
considered statistically significant when p < 0.05.  
 
I.4 Results 
Differential expression of PBMC genes after HE4 exposure 
To identify differentially expressed genes after HE4 exposure, modified subtractive 
hybridization was performed. PCR products of the differentially expressed genes were 
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cloned into pUC19-TA vectors to create a differential cDNA library. PCR products 
from 252 HE4-induced and 253-HE4 suppressed gene colonies were sequenced 
resulting in the identification of 211 induced genes and 208 suppressed genes. Among 
the identified genes, 23 induced and 15 suppressed sequences showed no significant 
similarity (NSS) to known genes in available nucleotide databases. Among the 208 
suppressed genes, OPN emerged as the most frequently identified gene (6 times out of 
253 sequences, 2.4%; Table 1). 
 
HE4 reduces OPN expression in PBMCs 
HE4-induced suppression of osteopontin in PBMCs was then confirmed via three 
modalities: flow cytometry, quantitative PCR (qPCR), and ELISA using PBMCs from 
four individual donors. First, PBMCs were cultured with recombinant human HE4 
(rHE4; 0.01 g / mL) for 24 hours and collected for flow cytometry analysis. Protein 
expression of OPN in CD3+ PBMCs (T cells) was found to be significantly reduced 
with HE4 exposure (48.8 ± 1.0 % vs 37.4 ± 1.0 %; p < 0.05; Figure 1A). PBMCs were 
harvested after a 6-hour incubation with rHE4 (0.01 g / mL), revealing a 0.70 ± 0.03-
fold reduction in OPN mRNA production (Fig 1B). PBMCs were then exposed to 
rHE4 (0.01 g / mL) for 24 hours and concentrations of OPN in the cell lysates and 
the culture supernatants were measured by ELISA. The concentrations of OPN in 
lysates (159.82 ± 3.14 vs 103.61 ± 3.23 pg / mL, p < 0.01) and culture supernatants 
(53.37 ± 3.14 vs 30.08 ± 3.48 pg / mL, p < 0.01) were also decreased with HE4 
exposure (Figure 1C).  
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HE4-mediated IL-12 and IFN- reduction in PBMCs is reversible with 
supplementation of OPN 
In lipopolysaccharide-stimulated macrophages, OPN has been shown to enhance IL-
12 production and suppress IL-10 production, thereby promoting Th1 activity (17, 18). 
In order to estimate the impact of HE4 on PBMCs, transcriptional expression and 
protein levels of Th1 related cytokines IFN- and IL-12 were evaluated. Cells were 
incubated with either: (a) vehicle control, (b) 0.01 g / mL rHE4 or (c) 0.01 g / mL 
of rHE4 and 20 pg / mL rOPN for 6 hours and cell lysates and/or culture supernatants 
were taken for qPCR and ELISA. As shown in Figure 2A, relative expressions of IL-
12B and IFN- mRNA were decreased (61% and 69% respectively) upon treatment 
with rHE4. This suppression was partially reversed by the addition of recombinant 
OPN (rOPN) to culture conditions. Protein expression, as determined by ELISA, is 
shown in Figure 2B. IL-12 concentrations, both in lysates and culture supernatants, 
were reduced after HE4 exposure (4.81 ± 0.17 to 2.05 ± 0.08 pg / mL in cell lysate and 
7.17 ± 0.26 to 3.56 ± 0.20 pg / mL in supernatant). The addition of rOPN resulted in a 
nearly complete reversal of HE4-mediated IL-12 suppression. Similarly, IFN-
 concentrations in the cell lysates and supernatant decreased significantly with rHE4 
treatment (from 35.55 ± 1.03 to 14.41 ± 1.10 pg / mL and from 19.92 ± 0.82 to 11.10 
± 0.59 pg / mL, respectively) and the addition of rOPN again caused recovery of the 
cytokine levels.  
 
Conditioned media from HE4-treated PBMCs enhanced the viability, proliferation, 
and invasiveness of ovarian cancer cells  
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In order to assess the effects of PBMC-produced soluble factors on cancer cell 
activity, SKOV3, an immortalized ovarian cancer cell line, was incubated with the 
conditioned media from PBMC cultures (2 x 106 / mL density) with or without rHE4. 
SKOV3 cells cultured with HE4-treated PBMC media showed significantly higher 
viability than cells cultured with the HE4-depleted PBMC conditioned media at 48 
hours (1773.84 ± 436.38 vs. 3081.17 ± 348.03, p < 0.01) and 72 hours (3146.67 ± 
494.87 vs. 4568.84 ± 407.74, p < 0.01; Figure 3A). Next, a cell migration assay was 
employed to determine whether conditioned media from rHE4-exposed PBMCs 
affects ovarian cancer migration as a surrogate of metastatic capability. The SKOV3 
cells that were incubated with HE4-exposed PBMC media showed more extensive 
migration than control cells (RFU of 1147.21 ± 365.09 vs. 3138.14 ± 419.66, p < 0.01, 
Figure 3B). Immunohistochemistry using anti-Ki67 was performed to evaluate the 
proliferation of SKOV3 cells in the presence of rHE4-exposed PBMC media or 
vehicle-exposed conditioned media. The proliferation rate of tumor cells in HE4-
exposed PBMC conditioned media was higher than control media (63.8 ± 18.1 vs 39.9 
± 7.6 %, p < 0.01, Figure 3C). These findings suggest that PBMCs alter their soluble 
factor release under the influence of rHE4, thus enhancing the viability, proliferation 
and migration capabilities of the cultured ovarian cancer cells. 
 
HE4 inhibition increases ovarian cancer susceptibility to PBMC-mediated cytotoxicity 
In order to evaluate the impact of native (tumor-cell produced) HE4 on PBMCs, 
SKOV3 cells were co-cultured with PBMCs after stable transfection with HE4 
specific shRNA (shHE4) or a scrambled oligonucleotide control plasmid (SO). Clones 
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of shRNA transfected cells were tested for their phenotype by western blotting and 
ELISA (Figure S5).  After a 2-hour incubation at 37 °C, the effector cells were washed 
away and the target cells were analyzed by flow cytometry. The silencing of HE4 in 
SKOV3/PBMC co-cultures led to a significant increase in IL-12 and IFN 
concentrations (Table 2). As shown in Figure 4, HE4 silencing also increased tumor 
cell susceptibility to PBMC cytotoxicity, an effect that was reversed by the addition of 
rHE4. Furthermore, this “rescue” by rHE4 was at least partially abrogated by the 
addition of recombinant IL12 (rIL-12) or recombinant IFN- (rIFN-) to the culture 
conditions. These findings suggest that the native HE4 production by ovarian cancer 
cells is critical to cell-mediated cytotoxicity resistance.  
 
Ovarian cancer patient prognosis correlates to the number of intra- and peri-tumoral 
CD3+ T cells and stromal OPN-producing cells  
Twenty biopsies from high-grade serous ovarian cancer patients were evaluated by 
dual fluorescent stain with antibodies against CD3 and OPN (Table 3). In the tumor 
segments of the biopsy specimen, some CD3- tumor cells showed high OPN 
expression, while in the stromal area of the biopsy the principal OPN+ cells were 
CD3+ T cells (Figure 5A). A significant portion of the stromal CD3+OPN+ cells was 
accompanied by strong OPN staining in their cytosols or the surrounding areas (Figure 
5B). In order to investigate the clinical relationship of HE4, OPN and CD3, numbers 
of T cells (CD3+) and total OPN+ cells were correlated with pre-operative serum HE4 
level (available for 13 patients) or PFS duration (available for 16 patients). The 
numbers of CD3+ infiltrating T cells, both in the tumor and stroma, were directly 
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proportional (tumor, r = 0.541, p = 0.03; stroma, r = 0.512, p = 0.02) to the patients’ 
PFS duration (Figure 5C). Additionally, the number of OPN+ cells, both in tumor and 
stroma, were in inversely proportional (tumor; r = -0.635, p = 0.019, stroma; r = -
0.582, p = 0.037) to serum levels of HE4. Moreover, the number of OPN+ cells in the 
stroma (but not in the tumor) were directly proportional to the patients’ PFS duration 
(r = 0.711, p = 0.002; Figure 5D). These findings suggest that tissue infiltrating T cells 
play a critical role in the suppression of ovarian cancer progression.  
 
I.5 Discussion 
HE4 is known to be highly overexpressed in ovarian cancer, but its causal relationship 
to ovarian tumorigenesis has not been firmly established. Emerging studies suggest 
that HE4 overexpression promotes ovarian tumor growth and imparts strong resistance 
against the most commonly used chemotherapeutics (20-24). Accordingly, serum HE4 
level is an early predictor of platinum resistance (9, 23), and ovarian cancer patients 
that experienced greater HE4 reduction during neoadjuvant chemotherapy exhibited 
improved overall survival (24). Our study has shown a novel role for HE4 in the 
inhibition of immune cell activity through OPN suppression. We identified the gene 
for OPN, SPP1, as the most prominently suppressed gene in PBMCs in response to 
HE4 exposure in vitro. Additionally, HE4 was found to downregulate OPN production 
in CD3+ T cells. It is important to note that the changes in OPN expression in T cells 
after HE4 exposure are quite modest according to the flow cytometric analysis, and 
this raises the question of whether these small differences translate into functional 
consequences. However, the changes in OPN levels determined by qPCR and ELISA 
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(Figure 1B and C) appear much more robust. These findings suggest that the secretion 
of OPN is an important factor to include in the assessment of the biological response 
to HE4. In accordance with this hypothesis, we confirmed suppressed secretion of 
OPN-induced cytokines IL-12 and IFN- in the rHE4 exposed PBMCs HE4’s 
inhibition of immune cell function was further clarified by our co-culture experiments 
showing reduced antitumoral cytotoxicity. 
OPN is primarily considered a pro-tumorigenic protein. In various types of cancers, 
serum OPN levels are directly proportional to degree of malignancy and inversely 
proportional to patient survival (25-27). OPN also plays a critical role in tumor 
formation and growth by promoting cancer cell survival, proliferation, metastasis, and 
angiogenesis (28, 29). On the other hand, some studies describe anti-tumor effects of 
OPN (30-33). Among them, Crawford et al., with elegantly designed cancer cell 
inoculation experiments using OPN null mice, demonstrated that host-derived OPN 
acted as a chemoattractant to enhance the host defense activity of macrophages, 
whereas tumor-derived OPN inhibited macrophage function to enhance the growth or 
survival of cancers (30). In our study, the number of OPN+ cells in stroma (mainly 
CD3+ T cells), but not in tumor (mainly CD3- tumor cells), correlated positively to 
patients’ PFS durations. The dichotomic function of OPN presented by Crawford et al. 
may serve as an explanation of the findings in the present study. 
In summary, this study is the first to implicate HE4 in ovarian cancer immune escape 
and provide the rationale for targeting HE4 to restore normal tumor immune editing.  
We are currently working to identify small molecules and/or neutralizing antibodies to 
further validate the utility of HE4 inhibition as a novel immunotherapeutic in the 
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treatment of ovarian cancer. However, several barriers remain in the achievement of 
this objective. For example, PBMCs in ovarian cancer patients may already be 
exposed to a chronically high level of HE4, which may have differing effects than the 
acute exposure performed in our study. Secondly, due to multiple complicated steps in 
the subtractive hybridization procedure, this study stands on the data from a single 
donor. The benefit of this experimental strategy lies in perspicuous outcomes; 
however, it also introduces inherent limitations in interpretation of the results. To 
begin to circumvent this pitfall, we validated the HE4-mediated downregulation of 
OPN using flow cytometry, qPCR, and ELISA in PBMCs from four healthy donors. 
This issue will be further addressed in subsequent studies on HE4. Lastly, it is 
important to note that OPN is known to play a role in humoral immunity (34-36). 
Further studies are required to fully understand the role of HE4 and OPN in humoral 
immunity in relation to ovarian cancer. Additionally, as we showed in Table 1 that 
PBMCs modulated a variety of genes in response to HE4 exposure. It is therefore very 
likely that other factors, besides osteopontin, are also contributing to in the inhibitory 
effect of HE4 on the immune system. Further analysis of the functions of these genes, 
and how they are associated with HE4, is warranted.   
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Figure I.1 HE4 downregulates expression of OPN in PBMCs. 
 (A) Two-color flow cytometric analysis of PBMC following a 24-hour incubation 
with 0.01 g / mL of rHE4 (HE4) or vehicle (CTR). 2D-scatterplots of OPN (Alexa 
Fluor 647) and CD3 (FITC) are shown. The numbers on the scatterplots represent 
mean ± SEM % of each quadrant.  (B) OPN transcription in response to a 6-hour 
incubation with 0.01 g / mL rHE4 (HE4) or vehicle (CTR) were evaluated by real 
time PCR. A bar graph represents relative expression levels against control. (C) OPN 
concentrations of PBMC lysates and culture supernatants after a 24-hour incubation 
with 0.01 g / mL of rHE4 (HE4) or vehicle (CTR) were evaluated by ELISA. All the 
experiments were done with PBMCs from four individual donors and repeated 3 (A), 
9 (B) and 10 (C) times. The mean is shown in the bar graphs; error bars represent 
SEM (n > 10). * p < 0.05, **p < 0.01. 
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Figure I.1 
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Figure I.2 HE4 suppresses expression and secretion of IL-12 and IFN- by PBMCs. 
(A) PBMCs were incubated for 6 hours in serum free media under the indicated 
conditions (vehicle, 0.01 g / mL rHE4 and rHE4 + 20 pg / mL of rOPN). After a  
6- hour incubation, transcription levels of IL-12B (p40) and IFN- were evaluated by 
real time PCR. A bar graph represents relative expression levels against control. (B) 
The concentrations of IL-12AB (p70) and IFN- in the cell lysates and the culture 
supernatants from 24-h incubation under the same conditions were measured by 
ELISA. All the qPCRs and ELISAs were done with PBMCs from four individual 
donors. Each assay was repeated 4 times (qPCR) or 10 times (ELISA). The mean is 
shown; error bars represent SEM. * p < 0.01. 
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Figure I.2 
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Figure I.3 Responses of SKOV3 and OVCAR8 human ovarian cancer cell lines to  
PBMC conditioned media. 
 (A) Cells were incubated with conditioned media from the PBMC culture treated with 
vehicle (blue line) or rHE4 (red line). The cell viabilities were assessed at 24, 48 and 
72 hours after treatment (n = 10 for 0 hours, n = 8 for 24, 48 and 72 hours). (B) Cell 
migration activities with conditioned media were assessed at 24 hours of incubation (n 
= 10).  (C) Ki67 immunohistochemistry staining was performed on SKOV3 / 
OVCAR8 cell lines incubated with the PBMC conditioned media for 24 hrs. Ki67+ 
cells are identified with red nuclear staining (upper panel). Bar graph (lower panel) 
represents the percentage of Ki67+ cells in total countable cells under 200x fields (n = 
6).  Scale bar: 50 m. The mean is shown; error bars represent SEM (n = 10). * p < 
0.05, ** p < 0.01. 
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Figure I.3 
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Figure I.4 Flow cytometric analysis of the cytotoxicity of mononuclear cells against 
SKOV3 tumor cells.  
Cell membranes of SKOV3 (target) cells were labeled with DiOC18(3) fluorescent dye 
and then incubated with PBMCs in the presence of propidium iodide (PI) as a marker 
of cell death.  After washing away the non-adherent cells (PBMCs), the PI positive 
tumor cells were quantitated via flow cytometry (upper panel). The numbers on the 
histograms represent mean percentage of each bisection. The bar graph (lower panel) 
represents percentages of PI positive (dead / dying) cells in various culture conditions. 
The mean is shown; error bars represent SEM (n > 10). * p < 0.01, **p < 0.05. 
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Figure I.4 
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Figure I.5 Confocal immunofluorescent analysis of CD3 and OPN expression in 
biopsy samples.  
Twenty biopsies (listed in Table 3) were evaluated.  (A) Stromal and tumoral CD3+ 
cells and OPN+ tumor cells are indicated by arrowhead. A biopsy from a benign 
serous tumor (Benign) and an uninvolved section of oophorectomy (Normal) were 
utilized as a negative control (B). Enlarged image depicting image co-staining of 
stromal and tumoral CD3+/OPN+ T cells in their cytosol or the surrounding area (C, 
D). Graphic representations of Spearman's rank correlations between the numbers of 
CD3+ or OPN+ cells and clinical parameters. CR; corrected ranks. 
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Figure I.5 
Figure I.5 a & b  
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Table 1
Genes suppressed in response to HE4
Frequency ID gene name
15 NSS no significant similarity
6 NM_001040058 secreted phosphoprotein 1 (SPP1), transcript variant 1
3 NM_015574 ankyrin repeat domain 17 (ANKRD17)
3 NM_001693 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 (ATP6V1B2)
3 NM_000206 interleukin 2 receptor subunit gamma (IL2RG)
3 NM_022818 microtubule-associated protein 1 light chain 3 beta (MAP1LC3B)
3 NM_001243121 phosphodiesterase 4A (PDE4A)
3 NM_080792 signal regulatory protein alpha (SIRPA)
3 NM_015131 WD repeat domain 43 (WDR43)
2 NM_001025604 arrestin domain containing 2 (ARRDC2)
2 NM_001164755 aspartate beta-hydroxylase (ASPH)
2 NM_032408 bromodomain adjacent to zinc finger domain, 1B (BAZ1B)
2 NM_002985 chemokine (C-C motif) ligand 5
2 AC132216 chromosome 11, clone RP13-786C16
2 NC_018926 chromosome 15, alternate assembly CHM1_1.1
2 NM_001291549 cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)
2 NM_014280 DnaJ (Hsp40) homolog, subfamily C, member 8 (DNAJC8)
2 XM_011535514 eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)
2 XM_011518416 family with sequence similarity 120A (FAM120A)
2 NM_020447 family with sequence similarity 219 member B (FAM219B)
2 NG_029887 golgin A3 (GOLGA3)
2 NM_002107 H3 histone, family 3A (H3F3A)
2 NM_001128619 leucine zipper protein 6 (LUZP6)
2 NM_002463 MX dynamin-like GTPase 2 (MX2)
2 NM_004687 myotubularin related protein 4 (MTMR4)
2 NM_001251855 phosphoinositide-3-kinase regulatory subunit 5 (PIK3R5)
2 NM_000437 platelet-activating factor acetylhydrolase 2, 40kDa (PAFAH2),
2 NR_049751 reticulon 3 (RTN3)
2 NM_001198719 retinoblastoma binding protein 7 (RBBP7)
2 NM_001028 ribosomal protein S25 (RPS25)
2 XM_011534644 serine/threonine kinase 10 (STK10)
2 NM_001242933 sorting nexin 1 (SNX1)
2 XR_241300 splicing factor 3b, subunit 1, 155kDa (SF3B1)
2 NM_181892 ubiquitin-conjugating enzyme E2D 3 (UBE2D3)
2 NM_006007 zinc finger, AN1-type domain 5 (ZFAND5)
1 159 genes
Table I. 1 Genes suppressed in response to HE4  
 
 
 
 
 
 92 
 
 
Table I. 2 Concentrations of IL-12, IFN-γ and HE4 in co-culture medium 
   
  
 Concentrations of IL-12, IFN- and HE4 in co-culture 
medium   
Target Effector IL-12 (ng/mL) INF- (ng/mL) HE4 (pM) 
SC - - - 534.15±41.81 
SC + 14.84±0.48 177.20±1.07 639.01±50.38 
shHE4 - - - 174.12±18.55* 
shHE4 + 31.95±0.68** 417.74±3.54** 237.91±34.24** 
SC; SKOV3 with scrambled oligo, shHE4; SKOV3 with 
HE4 shRNA 
 mean ± SE is shown (n = 10) 
  *p<0.01 vs. SC, **p<0.01 vs.SC + Effector cells 
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Table I.3 Clinical Parameters of Donors  
Table 3
Clinical parameters of donors of biopsies 
pre-OP sHE4* PFS**
Sample ID (pmol/mL) (months)
S10-10110 174 10
S10-10726 na 16
S10-15910 na 25
S10-17790 376 12
S10-18470 529 22
S10-4387 462 31
S10-5618 na 9
S10-5842 na na
S10-6697 150 na
S10-7183 1232 na
S11-1189 3289 8
S11-2223 550 28
S11-2493 591 37
S11-2684 3255 24
S11-3415 na na
S11-622 na 38
S11-6675 4702 16
S11-6721 na 64
S11-7794 410 38
S11-8032 623 21
*  pre-operation serum HE4
**  progression-free survival
na; not available  
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II.1 Abstract 
 
Objective  
Selective overexpression of Human epididymal secretory protein 4 (HE4) points to a 
role in ovarian cancer tumorigenesis but little is known about the role the HE4 gene or 
the gene product plays. Here we examine the role of the secretory glycoprotein HE4 in 
ovarian cancer immune evasion.  
Methods  
Through the modified subtractive hybridization analyses of human peripheral blood 
mononuclear cells (PBMCs), we have characterized gene targets of HE4 and 
established a preliminary mechanism of HE4-mediated immune failure in ovarian 
tumors.  
Results  
Dual specificity phosphatase 6 (DUSP6) emerged as the most upregulated gene in 
PBMCs upon in vitro exposure to HE4. CD8+ cells and CD56+ cells found to be 
sources of the upregulated DUSP6. The HE4 exposure enhanced Erk1/2 
phosphorylation specifically in these cell populations and the effect was erased by co-
incubation with DUSP6 inhibitor, (E)-2-benzylidene-3-(cyclohexylamino)-2,3-
dihydro-1H-inden-1-one (BCI).  In co-culture with PBMC, HE4-silenced SKOV3, a 
human ovarian carcinoma cell line, exhibited enhanced proliferation with exposure to 
the external HE4; this effect was partially attenuated by adding BCI to the culture. 
Additionally, the reversal effects of BCI were erased in the co-culture with CD8+ / 
CD56+ cell deprived PBMC.  
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Conclusion 
Taken together, these findings show that DUSP6 is a suppressor of the cytotoxicity of 
the CD8+ and CD56+ lymphocytes and HE4 enhances tumorigenesis of ovarian cancer 
through the compromised cytotoxicity of the CD8+ and CD56+ cells by upregulation 
of self-produced DUSP6, which acts as an autocrine factor.  
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II.2 Introduction 
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death in women, 
and the deadliest gynecologic cancer. The American Cancer Society estimates that in 
2017, there will be an estimated 22,440 new cases of EOC and 14,080 deaths in the 
United States [1]. Only 15% of patients are diagnosed at an early stage when the 
disease is fundamentally curable, keeping the 5-year survival rate at a dismal 46% [2]. 
Recurrence following initial treatment is common, occurring in approximately 80% of 
cases, and all patients with recurrent disease eventually succumb to their illness [3]. 
These dire statistics highlight the need for continued research into improved diagnostic 
and treatment options for EOC.  
Despite continued efforts, there remains a lack of effective treatments for EOC. 
Standard first-line therapy consists of debulking surgery followed by taxane-platinum 
chemotherapy[3]. Other targeted therapies are also employed, including the 
antiangiogenic drug bevacizumab and the PARP inhibitor olaparib; however, these 
treatments have not led to an improvement in overall survival [4]. One promising new 
area of investigation lies in understanding how tumors develop immune tolerance and 
evade elimination by cytotoxic lymphocytes. Immune checkpoint molecules such as 
PD-1, CTLA4, TIM3, IDO, and others, suppress T cell activation and help tumor cells 
escape targeting and elimination by the immune system [5]. Nivolumab, a monoclonal 
antibody against PD-1, is expressed on T cells and suppresses their activation upon 
binding of its tumor cell associated ligands, PDL1/PDL2, has greatly improved 
survival for metastatic melanoma patients [6]. PD-1 has also been studied in relapsed 
platinum-resistant EOC; however, overall response rates for EOC do not exceed 15% 
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[7]. This inefficacy of immune checkpoint inhibitors is likely due to compensatory 
immune suppressive pathways [8,9], or activation of oncogenic pathways that promote 
immune tolerance [5]. Overall, we require a greater understanding of factors that 
contribute to immune evasion in EOC in order to develop treatments that reactivate the 
body’s immune response to tumors.  
Human epididymis protein-4 (HE4) is a member of the whey acidic four-disulfide core 
protein family [10]. It is elevated in tumor tissue and serum of EOC patients, and is 
used as part of the Risk of Ovarian Malignancy Algorithm (ROMA)—along with 
CA125 and menopausal status—for the diagnosis and management of EOC [11, 12]. 
ROMA shows greater sensitivity and specificity for the detection and monitoring of 
EOC than the Risk of Malignancy Index, which uses CA125, pelvic sonography, and 
menopausal status [12]. HE4 also has the advantage of presenting fewer false positives 
than CA125 in the case of benign gynecologic disorders [11, 13]. In vitro and in vivo 
studies have shown that HE4 promotes multiple aspects of ovarian cancer aggression, 
including growth and proliferation; invasion, migration, and adhesion; 
chemoresistance, and anti-estrogen resistance [14–23]. Clinically, patients with high 
levels of serum HE4 have greater chemoresistance and worse prognosis [22, 24–26]. 
We hypothesized that HE4 may also promote immune evasion in EOC. We began to 
test this hypothesis by determining HE4-mediated gene expression in peripheral blood 
mononuclear cells (PBMCs), and went on to evaluate the effect of HE4 and one of its 
targets, DUSP6, on immune cell function and cytotoxicity against ovarian cancer cells.  
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II.3 Methods 
Subtractive hybridization and TA-cloning 
5 x 107 PBMCs from single donor were suspended in 5 mL of serum free RPMI1640 
medium (Invitrogen, 31800) and incubated with or without 0.01 g/mL of rHE4 
(Abcam, ab184603) for 6 hours. Then, total RNA was isolated using TRIzolTM 
Reagent (Invitrogen, 15596018). Next, mRNA was purified using MagnosphereTM 
UltraPure mRNA Purification Kit (Takara-Clontech, 9186). From the 5 g of mRNA, 
subtractive cDNA libraries were constructed using PCR-SelectTM cDNA Subtraction 
Kit (Takara-Clontech, 637401) following the manufacturer’s protocols. PCR products 
of the differentially expressed genes were cloned into a pUC19-TA vector. Top 10 
competent cells (Invitrogen, C404003) were transformed with the clones and were 
seeded on a Xgal/IPTG containing LB/ampicillin plates. The colonies of clones 
containing the inserts were selected by blue/white selection and were amplified by 
direct colony PCR using LA Taq® DNA polymerase (Takara-Clontech, RR002A) and 
M13 primers. 
 
Cell culture 
Primary human PBMCs were obtained under the auspices of Women & Infants 
Hospital IRB approval from total blood of four individual volunteer by density 
gradient centrifugation using Histopaque®-1077 (Sigma-Aldrich, 10771). The human 
ovarian tumor cell line, SKOV3, human NK cell line, NK-92MI, human T cell line, 
TALL-104 and H9 were obtained from ATCC (HTB-77, CRL-2408, CRL-11386 and 
HTB-176, respectively). RPMI1640 was used for culturing PBMC and lymphocyte 
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lines and DMEM (Invitrogen, 31600) were used for SKOV3. Conditioned media were 
obtained from a 24-hour PBMC culture.  Residual rHE4 in the conditioned media was 
deprived as follows. Five mL of media was incubated with 10 g (100 L) of anti-
human HE4 antibody (Santa Cruz Biotechnology, sc-293473) for 1 hour at 4 degrees. 
And then, 100 mL packed volume of protein G coated sepharose beads (GE 
Healthcare Life Science, 17061801) were added to the media and incubated for 4 
hours at 4 degrees. After the incubation, the sepharose beads were removed by 
centrifugation and the supernatants were processed through sterile 0.2 m pore syringe 
filter. For the cell-mediated cytotoxicity assay, 1 x 106 target cells (SKOV3) were 
seeded on 6-well plates, and then were incubated overnight with complete media. The 
next day, cells were placed in serum free media for another overnight incubation and 
then 5 x 106 / mL of the effector cells (PBMCs) were added to the quiescent target 
cells. After a 12-hour incubation, the effector cells were washed away and harvested 
target cells were stained with 1 g / mL of propidium iodide with or without Alexa 
Fluor® 488 labeled annexin V (Invirogen, V13241). Some of the wells contained 0.01 
g/mL of rHE4 and 1 M of DUSP6 inhibitor, (E)-2-benzylidene-3-
(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI; Sigma-Aldrich, B4313). All 
experiments were performed under serum free condition.  
 
Flow cytometry 
FITC-labeled anti CD3, CD4, CD8, CD14, CD19 and CD56 antibodies were obtained 
from BD Biosciences (555916, 561005, 560960, 555397, 555412 and 562794, 
respectively). Alexa Fluor® 647-conjugated anti DUSP6 antibody was obtained from 
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Abcam (ab200751). Alexa Fluor® 647-conjugated anti phosphor-p44/42 MAPK 
antibody was obtained from Cell Signaling Technology (13148). After staining for cell 
surface markers (CD3, CD14, CD19 and CD56) the cell membrane was permeabilized 
by 0.2 % Triton X-100 and 0.2 % digitonin, and then stained for DUSP6 or phosphor-
p44/42-MAPK. Flow cytometric analysis was performed with FACSCanto system and 
FACSDiva software (BD Biosciences). 
 
Quantitative Real-Time PCR 
RNA was isolated from cells using TRIzol (Invitrogen, A33250) according to the 
manufacturer’s instructions. cDNA was synthesized using SuperScript III reverse 
transcriptase (Invitrogen, 18080093). qPCR was performed using Premix Ex-TaqTM II 
(Clontech-Takara, 639676) probes for DUSP6. All reactions were normalized using 
GAPDH as an endogenous control. Amplification data were analyzed using the Ct 
method.  
 
ELISA 
ELISA kits for HE4 and DUSP6 were obtained from MyBioSource (MBS280223 and 
MBS073193, respectively). The assays were performed following the manufacturer’s 
instruction. 
 
Western blotting 
Phosphorylation of Erk1/2 in NK-92MI, TALL-104 and H9 cell lines were assessed 
by western blotting. Antibodies against phosphorylated and total Erk1/2 MAPK were 
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obtained from Cell Signaling Technology (9101 and 4695). The results were 
visualized with SuperSignal™ West Pico chemiluminescent substrate (ThermoFisher 
Scientifics, 34080) and analyzed with the UN-SCAN-IT gel software for Windows 
(Silk Scientific Inc.). 
 
HE4 silencing with shRNA 
shRNA for human HE4 (Origene, TR318721) were transfected into SKOV3 using 
Lipofectamine® 2000 (Invitrogen, 11668) following the manufacture’s instruction. 
Individual single cells were selected by culturing under the pressure of 5 g / mL of 
puromycin (Research Products International, 58-58-2).   
 
Cell viability assay 
1 x 103 / well SKOV3 cells were seeded in a 96-well culture plate. After overnight 
incubation with serum free medium, 5 x 106 /mL of effector cells (PBMCs) were 
added to the quiescent cells. The cell viabilities were evaluated at 24, 48 and 72 hours 
using fluorescent based CEllTiter-Blue® (Promega, G8080) and Spectra Max Gemini 
EM fluorescent micro plate reader (Molecular Devices). 
 
Immunohistochemistry 
0.5 x 104 / chamber of SKOV3 cells were seeded in a 4-chamber slide. After overnight 
incubation with serum free medium, 5 x 106 /mL of effector cells (PBMCs) were 
added to the quiescent cells and the cells were cultured for 48 hrs. Ki67 positive cells 
were counted in twenty of 200x fields. A mouse anti-Ki67 monoclonal antibody was 
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purchased from BD Biosciences (550609). An alkaline phosphatase (ALP) labeled 
anti-mouse IgG secondary antibody and an ALP substrate kit were obtained from 
Vector laboratories (AP-2000, SK-5100). 
 
Depletion of CD8+ and CD56+ cells from PBMCs 
CD8+ and CD56+ cells were removed from PBMC using magnetic CD8 and CD56 
MicroBeads (Miltenyi Biotec, 130-045-201 and 130-050-401) with autoMACS cell 
separator (Miltenyi Biotec, 130-092-545). Briefly, 5 x 107 of PBMC was suspended in 
60 L of separation buffer (PBS, pH 7.2 with 0.5 % BSA and 2 mM EDTA), and then, 
20 L each of CD8 and CD56 MicroBeads were added to it, followed by 15 minutes 
incubation at 4 degrees. After washing, resuspended the cells in 500 L of the 
separation buffer and proceed to magnetic separation using autoMACS® Columns 
(Miltenyi Biotec, 130-021-101). Unlabeled cells that pass through were collected and 
combined with total effluent from washed column.  
 
Statistics 
Data ware expressed as average ± SEM of at least four independent experiments. An 
unpaired, two-tailed Student t-test was used to determine significance. Multiple 
treatments were analyzed by using one-way ANOVA followed by Ryan’s multiple 
comparison test. Differences between groups were considered statistically significant 
when p < 0.05. 
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III.4 Results 
Differential expression of PBMC genes after HE4 exposure 
To identify differentially expressed genes after HE4 exposure, modified subtractive 
hybridization was performed. PCR products of the differentially expressed genes were 
cloned into pUC19-TA vectors to create a differential cDNA library. PCR products 
from 250 each of HE4-induced and HE4-suppressed gene colonies were sequenced 
resulting in the identification of 209 induced genes and 206 suppressed genes. Among 
the identified genes, 20 induced and 13 suppressed sequences showed no significant 
similarity (NSS) to known genes in available nucleotide databases. Among the 209 
induced genes, dual specificity phosphatase 6 (DUSP6) emerged as one of the most 
frequently identified genes (3 times out of 250 sequences, 1.2%; Table 1). 
 
HE4 induces DUSP6 expression in PBMCs 
HE4-induced upregulation of DUSP6 in PBMCs was then confirmed via three 
modalities: quantitative PCR (qPCR), ELISA and flow cytometry. First, PBMCs were 
harvested after a 6-hour exposure with recombinant human HE4 (rHE4; 0.01g/mL), 
revealing a 1.60 ± 0.13-fold increase (p < 0.01) in DUSP6 mRNA production (Figure 
1A). The concentrations of DUSP6 in PBMC lysates (9.38 ± 0.62 vs 15.62 ± 0.97 
ng/mL, p < 0.01) and culture supernatants (0.77 ± 0.10 vs 1.43 ± 0.14 ng / mL, p < 
0.01) after a 24-hour exposure to rHE4 were also increased (Table 2). PBMCs were 
then cultured with rHE4 for 24 hours and collected for flow cytometry analysis. 
Protein expression of DUSP6 in CD3+ PBMCs (T cells) was found to be significantly 
increased with HE4 exposure (34.4 ± 0.6 % vs 47.0 ± 3.2 % of total CD3+ cells; p < 
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0.05; Figure 1B left panel). The DUSP6 expression in CD56+ cells (NK/T cells, NK 
cells) was also increased to a lesser extent (34.1 ± 2.3 % vs 41.7 ± 1.7 % of total 
CD56+ cells; p < 0.05; Figure 1B right panel). In order to identify a T cell subset 
involved in the HE4 responsive induction of DUSP6, two-color flow cytometry using 
anti-DUSP6 antibody and anti-CD4 (helper T cell) or CD8 (cytotoxic T cell) 
antibodies were performed. As shown in Figure 2, after a 24-hour exposure to rHE4, 
CD8+ T cells (9.9 ± 0.8 % vs 1.9 ± 0.1 %; p < 0.01) but not CD4+ T cells (15.6 ± 1.4 
% vs 15.4 ± 1.5 %) showed significant DUSP6 induction. These finding suggested that 
the CD8+ and CD56+ cytotoxic mononuclear cells were responsible for the HE4 
responsive DUSP6 induction. 
 
CD8+ and CD56+ cytotoxic lymphocytes are targets of HE4 induced DUSP6 
In order to identify effector cells for the HE4 induced DUSP6, two-color flow 
cytometry using antibodies against phosphor-Erk1/2 (pErk1/2) and CD4, CD8, CD14, 
CD19 and CD56 were performed. Significant decreases of pErk1/2+ populations were 
observed in CD8+ (30.2 ± 2.4 % vs 4.3 ± 0.2 % in total CD8+ cells; p < 0.01) and 
CD56+ (32.3 ± 4.0 % vs 5.4 ± 0.6 % in total CD56+ cells; p < 0.01) cells after a 24 
hours rHE4 (0.01 g/mL) exposure, and the decreases were abrogated by co-treatment 
with 1 M of DUSP6 inhibitor, (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-
1H-inden-1-one (BCI) in both CD8+ cells and CD56+ cells (23.3 ± 0.7 % and 30.5 ± 
2.6 %, respectively; Figure 3A). Next, CD56+ NK cell line (NK92MI), CD8+ cytotoxic 
T cell line (TALL-104) and CD4+ helper T cell line (H9) were incubated with the 
conditioned media from a 24- hour PBMC culture with or without rHE4 and BCI for 1 
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hour. The lysates of the cells were used for western blotting to evaluate Erk1/2 
phosphorylation. As shown in Figure 3B, 1-hour incubation with the HE4 exposed 
PBMC conditioned media suppressed Erk1/2 phosphorylation in NK92MI cell (0.67 ± 
0.07-fold vs CTR, p < 0.01) and TALL-104 cell (0.56 ± 0.10-fold vs CTR, p < 0.01) 
but not in H9 cell (1.01 ± 0.03-fold vs CTR). The rHE4 responsive pErk1/2 
suppressions were abrogated by the PBMC conditioned media from co treatment with 
rHE4 and BCI in both NK92MI (0.90 ± 0.04-fold vs CTR) and TALL-104 (0.89 ± 
0.06-fold vs CTR). These findings suggested that the HE4 induced DUSP6 acts as an 
autocrine suppressor for Erk1/2 MAPK in CD8+ and CD56+ cytotoxic lymphocytes. 
 
HE4 attenuates ovarian cancer susceptibility to PBMC mediated cytotoxicity 
In order to evaluate the impact of HE4 on PBMC cytotoxicity against cancer cells, the 
human ovarian tumor cell line, SKOV3, was co-cultured with PBMCs (5 x 106 / mL 
density). To minimize the effect of native HE4 produced by tumor cell, the SKOV3 
cells were stably transfected with HE4 specific shRNA (shHE4). The effector cells 
(PBMCs) were washed away, and the target cells (SKOV3) were analyzed by three 
independent modalities: cell viability, Ki67 immunostaining, and flow cytometry for 
propidium iodide (PI) and annexin V. First, SKOV3 cells co-cultured with PBMC 
suspensions containing 0.01 g/mL of rHE4 showed significantly higher viability than 
cells cultured with the rHE4 free suspensions at 24 (1222.70 ± 29.48 vs. 1517.98 ± 
34.32, p < 0.01), 48 (2038.38 ± 55.94 vs. 3508.64 ± 164.98, p < 0.01) and 72 hours 
(1983.33 ± 100.41 vs. 2935.89 ± 116.47, p < 0. 01), and the increased viabilities were 
partially abrogated by adding 1 M of BCI to the culture (1295.68 ± 39.87, 2667.27 ± 
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95.13 and 2424.50 ± 105.70, at 24, 48 and 72 hours, respectively; Figure 4A). Second, 
immunohistochemistry using anti-Ki67 was performed to evaluate the proliferation 
activities of SKOV3 cells in the presence of PBMCs with or without rHE4 and BCI 
for 24 hours. The number of Ki67 positive tumor cells in rHE4-containing PBMC 
suspension was higher than the cells in rHE4-free suspension, and the increased 
activity was partially attenuated by adding BCI to the culture (27.6 ± 1.7 %, 68.5 ± 2.6 
% and 48.9 ± 2.3 %, respectively; Figure 4B). Finally, after a 6 -hour incubation at 37 
degrees, the effector cells were washed away and the target cells were analyzed by 2-
color flow cytometry using PI and Alexa Fluor® 488 labeled annexin V. As shown in 
Figure 4C, SKOV3 / PBMC co-cultures with rHE4 led to a significant decrease in 
populations of PI / annexin v double positive dying cells (24.3 ± 1.2 % vs. 13.4 ± 0.8 
%, p < 0.01), and the tolerance of the target cells was partially reversed by adding BCI 
to the culture (18.1 ± 0.6 %, p < 0.01 vs. CTR and HE4). These findings suggest that 
HE4 enhances tolerance of cancer cells against immunocompetent mononuclear cells 
via up-regulation of DUSP6 in PBMCs. In order to confirm involvement of CD8+ / 
CD56+ cytotoxic lymphocytes in the HE4 induced immunomodulation, the co-culture 
study was repeated using PBMCs deprived of CD8+ / CD56+ cells. As shown in Figure 
5A-C, all the effects of BCI shown in Figure 4 were erased in the CD8+ / CD56+ cell 
free co-cultures, suggesting that the cytotoxic lymphocytes play a pivotal role in the 
immunoediting by DUSP6 up-regulation in response to exposure to HE4. 
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II.5 Discussion 
Several studies from our laboratory and elsewhere have revealed multidimensional 
roles for HE4 in the pathogenesis of ovarian cancer, including the promotion of tumor 
growth, chemoresistance, anti-estrogen resistance, invasion, migration, and adhesion 
[14–23]. In this present study, we have begun to delineate another vital function of 
HE4 in disrupting immune cell function, which has implications for immune system 
targeting of tumor cells. DUSP6, which we found to be upregulated by rHE4 treatment 
in CD8+ T cells and CD56+ NK cell subsets of PBMCs, is likely one key mediator of 
this effect in these immune cell subsets. 
DUSP6 is a member of the DUSP family that dephosphorylates threonine and tyrosine 
residues on MAPK substrates. It specifically dephosphorylates ERK, a member of the 
MAPK family that also includes p38 and JNK. MAPKs are activated by growth 
factors, cytokines, integrin ligands, and stress signals to regulate growth, survival, 
apoptosis, and immune response in diverse cell types. Interestingly, DUSP6 is 
expressed at low levels in resting cells and is actually stimulated by ERK activation, 
promoting a negative feedback loop on ERK activity [27]. This early response of 
DUSP6 to ERK activation could explain the apparently contradictory activation of 
ERK by HE4 in cancer cells [14, 16, 17, 23] and our results showing that HE4 
upregulation of DUSP6 expression leads to suppression of ERK phosphorylation in 
PBMC subsets.  
Several reports reveal a role for DUSP6 in development, organogenesis, and cancer 
[27]. However, its effect on cancer progression is highly dependent upon the type of 
cancer and even the stage. For example, in pancreatic cancer, it is upregulated in early 
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stages but is often completely diminished as the tumor progresses towards the invasive 
ductal carcinoma state [28]. In lung cancer, it has been shown to act as a tumor 
suppressor [29]. Conversely, it is upregulated in glioblastoma and HER2-positive 
breast cancer [30, 31]. One report found that its downregulation in ovarian cancer 
results in hyperactivation of ERK and subsequent chemoresistance [32]. These 
discrepancies are likely due to variable deregulation of ERK signaling and 
compensatory pathways that are highly context dependent [27]. In contrast to the roles 
of the tumor producing DUSP6 on the tumorigenesis, the functions of DUSP6 
originated from immune cells have rarely been evaluated. 
Even less is known regarding the role of DUSP6 in immune cell function. Other 
members of the DUSP family, including DUSP1, DUSP2, and DUSP10, are known to 
have roles in immune response [27], and a few reports suggest that DUSP6 does as 
well. Elevated DUSP6 was shown to cause downregulation of ERK phosphorylation 
in CD4+ T cells in elderly individuals, who have suppressed immune responses [33]. 
Another report confirmed this age associated rise in CD4+ T cell DUSP6 expression, 
and found that young immunosuppressed patients with end stage renal disease have 
DUSP6 levels comparable to elderly healthy individuals [34]. One study found that 
DUSP6 downregulates ERK activity in CD4+ T cells and increases their regulatory T 
cell functions [35]. Together, these reports suggest that higher levels of DUSP6 
contribute to immune suppression. It has also been shown that DUSP6 is 
downregulated in T cells upon IL-2 withdrawal [36], and IL-2 was found to upregulate 
DUSP6 gene expression in T cells [37]. Since IL-2 stimulates cytotoxic T cell 
expansion and activation as well as that of immune suppressive regulatory T cells 
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[38], it remains to be determined how the IL-2 responsiveness of DUSP6 plays into its 
apparent effect on immune suppression, and how this relates to tumor immune 
response.  
Although much remains unknown regarding the specific effects of DUSP6 on cancer 
progression and tumor immunity, our findings begin to reveal some novel insights. We 
report for the first time that HE4-mediated upregulation of DUSP6 in CD8+ T cell and 
CD56+ NK cell subsets of PBMC cells leads to the inhibition of their cytotoxic 
activity against SKOV3 ovarian cancer cells. While DUSP6 has been connected to 
immune function of CD4+ T cells, our results reveal that the subsets of lymphocytes 
affected by DUSP6 are context dependent. Further investigation into the inhibitory 
effects of DUSP6 in these different populations will be illuminating. Moreover, we 
have begun to establish HE4 as a critical regulator of immune cell function, which 
deepens our understanding of the mechanistic role HE4 plays in ovarian cancer 
pathogenesis.  
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Figure II.1 HE4 upregulates expression of DUSP6 in PBMCs.  
(A) DUSP6 transcription in response to a 6-hour incubation with 0.01 g/mL rHE4 
(HE4) or vehicle (CTR) were evaluated by triplicated trials of real time PCR using 
PBMCs from four individual donors. (B) Two-color flow cytometric analysis of PBMC 
following 24-hr incubation with 0.01 g/mL of rHE4 (HE4) or vehicle (CTR). 2D-
scatterplots (upper panel) of DUSP6 (Alexa Fluor 647) and CD3 or CD56 (FITC) are 
shown. The lower panel shows bar graph from flow cytometric analyses using PBMCs 
from four individual donors. The mean ± SEM are shown. *p<0.05. 
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Fig. II.1 
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Figure II.2 HE4 upregulates expression of DUSP6 in peripheral CD8+ T cells.  
Two-color flow cytometric analysis of PBMCs following 24-hour incubation with 
0.01 g/mL of rHE4 (HE4) or vehicle (CTR). 2D-scatterplots (upper panel) of DUSP6 
(Alexa Fluor 647) and CD4 or CD8 (FITC) are shown. The lower panel shows a bar 
graph from flow cytometric analyses using PBMCs from four individual donors.  The 
mean using ± SEM are shown. *p<0.01. 
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Fig. II.2 
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Figure II.3 HE4 suppresses Erk1/2 phosphorylation in CD8+ and CD56+ cells via 
DUSP6 induction. 
 (A) Two-color flow cytometric analysis of PBMC following a 24-hour incubation 
with rHE4 (0.01 g /mL) and BCI (1 M) as indicated. 2-D scatterplots of phosphor-
Erk1/2 (Alexa Fluor 647) and CD8 or CD56 (FITC) are shown. Mean ± SEM from 
analyses with four individual donors are shown in the bar graph. (B) Immunoblotting 
for phosphor-Erk1/2 in CD56+ NK92MI, CD8+ TALL-104 and CD4+ H9 cells 
following a 1-hour incubation with the conditioned media from a 24-hour PBMC 
culture with rHE4 (0.01 g/mL) and BCI (1 M) in the indicated combinations. Blots 
of total Erk1/2 are shown as loading controls. Bar graph represents the relative band 
densities to controls. Mean ± SEM are shown (n=4). *p < 0.05, **p < 0.01. 
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Fig.II.3 
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Figure II.4 Responses of SKOV3 cells to co-culture with PBMCs 
(A) Cells were co-cultured with PBMC (5 x 106 / mL) with rHE4 (0.01 g /mL) and 
BCI (1 M) in indicated combinations. The cells viabilities were assessed at 24, 48 
and 72 hours of the culture (n = 10). (B) Ki67 immunohistochemistry staining was 
performed on SKOV3 cells co-cultured with PBMC for 24 hours. Ki67+ cells are 
identified with red nuclear staining. Bar graph represents the percentage of Ki67+ 
cells in total countable cells under 200x fields (n = 20). (C) Two-color flow cytometric 
analysis of SKOV3 following 6-hour PBMC co-culture with of rHE4 (0.01 g/mL) 
and BCI (1 M) as indicated. 2D-scatterplots of propidium iodide and annexin V 
(Alexa Fluor® 488) are shown. Bar graph represents the percentage of propidium 
iodide / annexin V double positive cells in total cells (n = 4). Mean ± SEM are shown 
in the bar graphs. *p < 0.01. 
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Fig.II.4  
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Figure II.5  
Responses of SKOV3 cells to co-culture with CD8+ / CD56+ cell free PBMCs  
(A) Cells were co-cultured with CD8+ / CD56+ cell-free PBMCs  with rHE4 (0.01 g 
/mL) and BCI (1 M) in indicated combinations. The cells viabilities were assessed at 
24, 48 and 72 hours of the culture (n = 10). (B) Ki67 immunohistochemistry staining 
was performed on SKOV3 cells co-cultured with CD8+ / CD56+ cell-free PBMCs for 
24 hrs. Ki67+ cells are identified with red nuclear staining. Bar graph represents the 
percentage of Ki67+ cells in total countable cells under 200x fields (n = 20). (C) Two-
color flow cytometric analysis of SKOV3 following 6 -hour CD8+ / CD56+ cell free 
PBMCs co-culture with of rHE4 (0.01 g/mL) and BCI (1 M) as indicated. 2D-
scatterplots of propidium iodide and annexin V (Alexa Fluor® 488) are shown. Bar 
graph represents the percentage propidium iodide / annexin V double positive cells in 
total cells (n = 4). Mean ± SEM are shown in the bar graphs. *p < 0.01.  
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Fig.II.5 
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Table II.1 Genes induced in response to HE4  
Frequency ID gene name 
23 NSS no significant similarity 
3 NG_033915 dual specificity phosphatase 6 (DUSP6) 
3 XM_017002424 
capping actin protein of muscle Z line alpha sub 
unit 1 (CAPZA1) 
3 NM_001402 
eukaryotic translation elongation factor 1 alpha 1 
(EEF1A1) 
3 XM_017000674 
FGR proto-oncogene, Src family tyrosone kinase 
(FGR) 
3 NM_001261446.1 thioredoxin reductase 1 (TXNRD1) 
3 NM_021109 thymosin beta 4, X-linked (TMSB4X) 
3 BC006364 tubulin folding cofactor D 
2 AK223032 beta actin variant 
2 AC008397.7 chromosome 19 clone CTC-251H24 
2 NM_001170330 chromosome 4 open reading frame 3 (C4orf3) 
2 AY430097 DAZ associated protein 2  (DAZAP2) 
2 NM_001005360  dynamin 2 (DNM2) 
2 NG_002350.4 
eukaryotic translation elongation factor 1 alpha 1 
pseudogene 5 (EEF1A1P5)  
2 NM_004468.4 four and a half LIM domains 3 (FHL3) 
2 NM_001077488 GNAS complex locus (GNAS) 
2 NM_001321232 histocompatibility (minor) HA-1 (HMHA1) 
2 NM_000206.2 interleukin 2 receptor, gamma (IL2RG) 
2 NM_001127605.2 lipase A, lysosomal acid (LIPA) 
2 NM_012335.3 myosin IF (MYO1F) 
2 XM_011541520 notch 2 (NOTCH2) 
2 NM_001165412 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 (NFKB1) 
2 NM_020820.3 
phosphatidylinositol-3,4,5-trisphosphate 
dependent Rac exchange factor 1 (PREX1) 
2 NM_001251855 
phosphoinositide-3-kinase regulatory subunit 5 
(PIK3R5) 
2 NM_201384.2 plectin (PLEC) 
2 NM_002952 ribosomal protein S2 (RPS2) 
2 NM_001007.4 ribosomal protein S4, X-linked (RPS4X) 
2 NM_000655 selectin L (SELL) 
2 NM_004252 SLC9A3 regulator 1 (SLC9A3R1) 
2 NM_022733.2 small ArfGAP2 (SMAP2) 
2 NM_001278206 solute carrier family 43, member 3 (SLC43A3) 
2 NM_025250.2 tweety family member 3 (TTYH3) 
2 BC050652.1 zinc finger, DHHC-type containing 16 
2 NM_004773  zinc finger, HIT-type containing 3 (ZNHIT3) 
2 XM_011516569 zyxin (ZYX) 
1   154 genes 
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Table II.2 DUSP6 concentration in cell lysates and culture media of PBMCs 
Cell lysates* Culture media** 
CTR HE4 CTR HE4 
9.38 ± 0.62 15.62 ± 0.97*** 0.77 ± 0.10 1.43 ± 0.14*** 
*I 2.5 mg/mL of total protein(ng/mL) 
**in 5 mL media of 5 x 106 PBMC culture 
The mean ± are shown, n = 10 / each group, ***< 0.01 vs CTR 
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III.1 Abstract 
Dual Specificity phosphatase 6 (DUSP6) is a phosphatase that deactivates 
extracellular-signal-regulated kinase (ERK). Since the ovarian cancer clinical 
biomarker human epididymis protein 4 (HE4) has been shown to interact with the 
ERK pathway, the objective of this study was to determine the relationship between 
DUSP6 and HE4 and begin to elucidate the role of DUSP6 in epithelial ovarian cancer 
(EOC). Western blot and quantitative PCR following knockdowns showed that HE4 
and DUSP6 levels were reduced with knockdown of the other protein in SKOV3 and 
OVCAR8 ovarian cancer cells. Furthermore, DUSP6 levels were upregulated in cells 
overexpressing HE4. Since HE4 has been shown to promote chemoresistance in EOC, 
the effect of DUSP6 on chemotherapeutic response was evaluated. MTS assay 
revealed a significant decrease in cell viability with pharmacological inhibition of 
DUSP6 using BCI in cells treated with carboplatin or paclitaxel, compared to 
treatment with single-agent chemotherapy alone. Quantitative PCR was used to 
evaluate gene expression responses to BCI, recombinant HE4 (rHE4), carboplatin, 
paclitaxel, and combinatorial treatments. DUSP6 inhibition with BCI altered 
expression of ERK pathway response genes, including early growth response protein 1 
(EGR1) and c-Jun. Expression of EGR1, a strong promotor of apoptosis, was higher in 
ovarian cancer cells co-treated with BCI and paclitaxel or carboplatin than in cells 
treated with chemotherapeutic agent alone. Alternatively, the expression of c-Jun, a 
proto-oncogene, decreased with co-treatment of BCI and paclitaxel or carboplatin. The 
effect of BCI on the expression of these two genes opposed the effect of rHE4 on their 
expression. Finally, expression levels of DUSP6 in EOC tissue were evaluated by 
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immunohistochemical staining and quantification of mean and maximum intensity or 
integrated optical density (IOD). Levels of DUSP6 were noted to be significantly 
upregulated in serous EOC tissue compared to adjacent normal tissue, and a positive 
correlation between HE4 and DUSP6 levels was observed by Spearman Rank 
correlation. Unpaired 2-tailed student t-test was employed to determine statistical 
significance of results. In conclusion, DUSP6 inhibition sensitizes ovarian cancer cells 
to chemotherapeutic agents and alters gene expression of ERK response genes. The 
ability to detect HE4 levels in EOC patients coupled with the established co-
dependence of DUSP6 with HE4, indicates that DUSP6 could plausibly function as a 
novel therapeutic target in EOC. 
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III.2 Introduction 
Epithelial ovarian cancer (EOC) remains the most common and deadly gynecologic 
cancer, responsible for 240,000 diagnoses and 152,000 deaths worldwide each year 
[1]. The 5-year survival rate remains at 35% [2], which is largely due to difficulty with 
early diagnosis, coupled with the frequency of chemoresistant recurrences [3]. 
Although a majority of EOC is initially responsive to chemotherapy, once the disease 
recurs, chemoresistance inevitably develops and the patient eventually will succumb to 
their illness [4]. Therefore, there is a need for improved diagnostic approaches, as well 
as novel treatment targets to combat chemoresistance.  
Human epididymis protein 4 (HE4) has been established as a novel clinical biomarker 
for EOC. Inclusion of preoperative levels of HE4 into the diagnostic Risk of Ovarian 
Malignancy Algorithm (ROMA) results in demonstrably improved specificity and 
sensitivity in detection and monitoring of the disease over Cancer Antigen 125 (CA 
125), pelvic sonography, and menopausal status [5]. Research has also shown its 
mechanistic involvement in promoting EOC pathogenesis, including the promotion of 
proliferation, chemoresistance, anti-estrogen resistance, adhesion, invasion, and 
migration [6–16]. One oncogenic pathway that has been shown to interact with HE4 in 
several studies is the extracellular signal regulated kinase (ERK) pathway. Several 
reports indicate that ERK activation is enhanced with HE4 treatment or 
overexpression, while ERK activation is reduced with HE4 knockdown [8, 14, 15]. 
Our lab has revealed a more complicated response of ERK to recombinant HE4 
treatment; specifically, we have observed downregulation of ERK phosphorylation at 
early time points, and upregulation at later time points [8]. Although the exact 
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mechanism of HE4 interaction with the ERK pathway is not clarified, it is well 
established that HE4 mediates ERK activation in EOC.  
Dual specificity phosphatase 6 (DUSP6) is a key negative regulator of ERK signaling 
via dephosphorylation of ERK at serine/tyrosine residues. ERK activation upregulates 
gene expression of DUSP6, which promotes a negative feedback loop on ERK 
activation [17]. DUSP6 has been shown to have differing effects on tumor progression 
depending on the tumor type. In pancreatic cancer, it is initially upregulated, but 
diminished at later stages, and is considered a tumor suppressor [18]. It is also 
considered a tumor suppressor in lung cancer [19]. However, in glioblastoma and 
HER-2 positive breast cancer, it has been shown to be upregulated [20, 21]. In gastric 
cancer, DUSP6 inhibition can overcome chemoresistance [22], and it has also been 
characterized as a therapeutic target in acute lymphoblastic leukemia [23]. One study 
in ovarian cancer suggested that it may act as a tumor suppressor [24]. The goal of the 
present study was to determine the relationship between HE4 and DUSP6 in EOC and 
begin to elucidate the role of DUSP6 in EOC.  
 
III.3 Methods 
Cell Culture, Treatments, and siRNA Knockdowns  
SKOV3 and OVCAR8 cells were obtained from ATCC and cultured in Dulbecco 
Modified Eagle Medium (DMEM) with 10% fetal bovine serum and 1% 
penicillin/streptomycin, in a humidified incubator at 37°C/5% CO2. Cells were plated 
at sub-confluent density the day before treatments. Cells were treated with 3.75 µM 
BCI (Sigma, B4313), 20 nM recombinant HE4 (My BioSource, MBS355616), 100-
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500 µM carboplatin (Sigma Aldrich, C2538), 10 nM paclitaxel (Sigma Aldrich, 
T7402), or control treatments (.037% DMSO and/or H20) for indicated time points. 
Knockdowns were performed using siRNA directed against DUSP6 (Santa Cruz, sc-
39000), HE4 LNA GapmeRs (Exiqon, 300600 Design ID 414262-1), control non-
targeting siRNA (Santa Cruz, sc-37007) or Negative Control GapmeRs (Exiqon, 
300610). Five µL lipofectamine 2000 (Invitrogen, 52887) was incubated at room 
temperature in 100 µL serum/antibiotic free DMEM. Meanwhile, siRNA was 
incubated separately in 100 µL serum/antibiotic free medium at a concentration of 2 
µM for 5 minutes. The tubes were combined and incubated at room temperature for 20 
minutes. The complex was added to cells cultured in DMEM with serum but no 
antibiotic to a final concentration of 100 nM. Cells were collected or underwent 
additional treatments after 48 hours. 
 
Western Blot  
Western blot was performed as previously described [9]. GAPDH was used as a 
loading control. Antibodies and dilutions used are as follows: 
DUSP6 (MyBioSource, MBS8516662, 1:500) 
HE4 (Santa Cruz, sc-293-473, 1:200) 
GAPDH (Cell Signaling, 2118, 1:2000)  
Phospho-ERK (Cell Signaling, 1:2000) 
ERK (Cell Signaling, 1:2000) 
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Densitometry  
Image J “analyze gel” function was used to perform densitometry analysis of western 
blot images in 8-bit TIFF format. Band densities were normalized to GAPDH, and the 
lowest value was set to 1 for plotted graphs. 
 
Quantitative RT-PCR  
Quantitative RT-PCR was performed as previously described [9]. Validated primers 
for DUSP6, EGR1, and c-JUN were purchased from realtimeprimers.com. Custom 
primer sequences (Invitrogen) are as follows: 
18s rRNA (F) – CCG CGG TTC TAT TTT GTT GG 
18s rRNA (R) – GGC GCT CCC TCT TAA TCA TG 
 
Cell Viability Assay 
Cells were seeded at 2 000 cells/well in 96-well plates and treated as described above. 
After 48 h, cell viability assays were performed by adding 10 µl/well of CellTiter 96® 
Aqueous One Solution Cell Proliferation MTS Assay (Promega, G3580), incubating at 
37°C/5% CO2 for 2 h, and reading absorbance at 492 nm. Results are displayed as 
percent survival of vehicle treated cells. 
 
Immunohistochemistry 
Immunohistochemical staining of an ovarian cancer microarray (US Biomax, 
OV802a) and patient tissues from the Women & Infants Pathology Department was 
performed as previously described [35], using antibodies for HE4 (Santa Cruz, sc-
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293473), DUSP6 (MyBioSource, MBS8516662). Confocal microscopy was 
performed by an independent imaging technician at the Rhode Island Hospital Digital 
Imaging Core Facility with a Nikon C1si confocal (Nikon Inc. Mellville, NY, USA). 
Two to three fields/sample were randomly selected based on DAPI staining, and 
minimum, mean, and maximum gray values were determined for each field. For the 
tumor microarray, normal adjacent tissues were used to set the threshold for positive 
staining. Integrated optical density (IOD) was calculated in serous samples using the 
mean values multiplied by the total area.  
 
Statistics  
Where statistics are shown, n≥3 biological replicates. Error bars represent standard 
deviation (STDEV) for quantitative PCR and MTS results, and standard error of the 
mean (SEM) for immunohistochemistry results. P-values were determined by 
unpaired, 2-tailed Student t-test. For correlation analysis, Spearman rank test was used 
to determine R value. Differences were considered statistically significant when p < 
0.05. 
 
III.4 Results 
HE4 and DUSP6 Levels Are Co-Dependent in Ovarian Cancer Cell Lines 
We first confirmed the upregulation of DUSP6 by HE4 by examining mRNA and 
protein levels in SKOV3 and OVCAR8 ovarian cancer cells stably overexpressing 
HE4 (clone 1 and clone 5, respectively) or their null vector (NV) counterparts. DUSP6 
mRNA was upregulated by HE4 overexpression (1.2)-fold (p<0.05) and (3.9)-fold 
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(p<0.05), in SKOV3 and OVCAR8 cells, respectively (Figure 1A-B). To determine 
the reciprocity of the relationship between HE4 and DUSP6, we performed transient 
siRNA knockdown of DUSP6 and LNA GapmeR knockdown of HE4. We observed 
that knockdown of HE4 protein resulted in a corresponding downregulation of 
DUSP6, and knockdown of DUSP6 resulted in a corresponding downregulation of 
HE4 (Figure 1C-F).  
 
Inhibition of DUSP6 Sensitizes Ovarian Cancer Cells to Chemotherapeutic Drugs 
Next, we wanted to begin to determine the function of DUSP6 in ovarian cancer cells. 
Since one well-known role of HE4 in EOC is the promotion of chemoresistance, we 
treated SKOV3 and OVCAR8 cells with a DUSP6 inhibitor (BCI) alone or in 
combination with paclitaxel or carboplatin, the standard of care chemotherapeutic 
agents in EOC. Treatment of cells with BCI alone resulted in a small but significant 
reduction in cell viability as determined by MTS assay – 86.3% and 84.7% in 
OVCAR8 and SKOV3, respectively. In both cell lines, co-treatment with BCI and 
carboplatin resulted in a synergistic effect on cytotoxicity compared to either treatment 
alone. Carboplatin alone treatment resulted in 89.8% and 86.8% survival in OVCAR8 
and SKOV3 cells, respectively, while BCI with carboplatin resulted in 33.9% and 
50.2% survival in OVCAR8 and SKOV3 cells, respectively. In OVCAR8 cells, a 
synergistic effect was noted with BCI and paclitaxel treatment as well, with survival 
reducing from 51.4% with paclitaxel alone to 25.3% with BCI and paclitaxel (Figure 
2A-B).  
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DUSP6 Inhibition Alters Expression of ERK Pathway Responsive Genes  
In order to determine how regulation of ERK signaling by BCI versus rHE4 might 
affect downstream gene expression, we treated cells with BCI alone or in combination 
with rHE4, paclitaxel, or carboplatin, and examined expression of the ERK pathway 
response genes EGR1 and c-Jun. EGR1 is a transcription factor involved in promoting 
apoptosis in many cancers [25–28], and has been shown to be involved in cisplatin 
resistance in esophageal and ovarian cancers [29, 25]. We have previously shown that 
HE4 suppresses EGR1 gene upregulation in response to cisplatin treatment of SKOV3 
cells [8]. On the other hand, c-Jun is an AP-1 transcription factor involved in 
promoting cell survival and growth [30, 31]. Treatment with BCI modestly 
upregulated EGR1 expression in both cell lines, while treatment with rHE4 
downregulated EGR1 expression—a result that is in agreement with our previous 
study showing HE4 suppresses cisplatin-mediated upregulation of EGR1. The effect 
of BCI on EGR1 expression was more apparent with rHE4 co-treatment, where it 
reversed the downregulation of EGR1 by rHE4. Furthermore, co-treatment with BCI 
and either paclitaxel or carboplatin upregulated expression of EGR1 compared to 
treatment with either chemo drug alone. These results show that BCI opposes the 
effects of HE4 on EGR1 expression and promotes EGR1 expression while suppressing 
c-Jun expression in cells exposed to chemotherapy drugs (Figure 3A-D).  
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DUSP6 Levels Are Upregulated in EOC Tissue Compared to Adjacent Normal Tissue, 
and Correlate with HE4 Tissue Levels 
To verify the clinical relevance of our findings, we performed immunohistochemistry 
of DUSP6 in an EOC tumor microarray and compared levels in serous 
adenocarcinoma samples (n=40) to levels in normal adjacent tissue (NAT; n=7). Mean 
intensity of DUSP6 was 545 (+/- 24.5) in EOC samples, and 432 (+/-19.6) in NAT 
(p=0.005). Moreover, maximal intensity was significantly greater in serous EOC 
samples than NAT. Maximum intensity was 1653 (+/-75.3) for EOC and 900 (+/-
110.3) for NAT (p=0.016), indicating that some areas of EOC exhibited particularly 
strong staining for DUSP6 (Figure 4A). Representative images are shown in Figure 
4B.  
In order to determine if a correlation exists between HE4 levels and DUSP6 levels in 
EOC, we co-stained for both proteins in the ovarian tissue microarray, and calculated 
correlations for mean intensity values and integrated optical density (IOD). Spearman 
Rank correlation test revealed a positive correlation between DUSP6 and HE4 mean 
intensities (R=0.45, p=0.0038) and IOD values (R=0.64, p=0.00001) (Figure 4C-D). 
Together, these results suggest that DUSP6 may be involved in promoting 
tumorigenesis in EOC, and corroborate our results indicating a relationship between 
HE4 and DUSP6.  
 
III.5 Discussion 
In this study, we have determined that HE4 and DUSP6 levels are co-dependent in 
ovarian cancer cells, and that these two proteins interact and are correlated in patient 
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tissue. Future studies are needed to elucidate the exact mechanistic relationship 
between DUSP6 and HE4. Studies by us and others have confirmed that HE4 activates 
ERK in ovarian cancer cells [8, 14, 15], while DUSP6 is a known negative regulator 
of ERK signaling [17]. Interestingly, despite the fact that HE4 and DUSP6 have 
opposing roles on ERK activation, they appear to produce similar effects on biological 
function of tumor cells. Our results show that activation of ERK by the DUSP6 
inhibitor BCI as opposed to HE4 produces very different effects on gene expression 
and cellular functions such as chemotherapy response.  
The two ERK responsive genes we have characterized show opposite expression 
patterns with BCI treatment. EGR1 is activated by ERK via the transcription factor 
ELK-1, and EGR1 is itself a transcription factor that activates expression of pro-
apoptotic genes [32]. A previous study by our lab showed that HE4 overexpression in 
SKOV3 cells suppresses cisplatin-mediated upregulation of EGR1 [8]. Here, we 
observe that HE4 downregulates EGR1 expression, which is consistent with these 
previous results. Conversely, BCI treatment opposes the effect of rHE4 on EGR1 
expression, indicating differing effects downstream of ERK activation by these two 
treatments. C-Jun, which is also an ERK responsive gene, is regulated oppositely as 
EGR1. rHE4 treatment upregulates expression of c-Jun, which is consistent with its 
role as a promoter of tumor growth and proliferation [6, 12, 13, 33, 34]. Meanwhile, 
BCI again opposes this effect in BCI and rHE4 co-treated cells. Furthermore, BCI 
suppresses chemotherapy-mediated increases in c-Jun levels. The effects of BCI on 
EGR1 and c-Jun together may contribute to the overall increased efficacy of BCI and 
chemotherapy treatment over chemotherapy alone.  
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The role of DUSP6 in EOC is not well studied. One report showed that DUSP6 
appears to function as a tumor suppressor in EOC [24], but our results suggest the 
opposite effect. Therefore, further study is needed to fully elucidate the role of DUSP6 
and determine if its function is context dependent. In general, DUSP6 remains an 
interesting protein, in that it has opposing roles in different tumor types. In some 
cancers, it appears to act as a tumor suppressor, while in others it acts to promote 
tumorigenesis and aggressive behavior [19–24]. Our results are consistent with a 
recent study by Wu et al. (2018) showing its involvement in cisplatin resistance in 
gastric cancer [22]. The authors observed an increase in phospho-ERK with BCI 
treatment, but a downregulation of the ERK-response genes RPS6KA1, EGR1, 
MMP2, MMP9, MYC, and ELK3. Furthermore, they found that BCI treatment 
enhanced cisplatin sensitivity in gastric cancer cells and in vivo xenografts. In our 
study, we observed different effects of DUSP6 inhibition on ERK-response genes 
depending upon gene function—namely, upregulation of the tumor suppressor EGR1 
and downregulation of the proto-oncogene c-Jun. Collectively, our study and the one 
by Wu et al. illustrate that the relationship between ERK activation and downstream 
gene activation is not straightforward and appears to be highly context-dependent. 
Therefore, although BCI serves to increase ERK activation, it has different effects on 
ERK response genes, which serve to enhance chemotherapy efficacy.  
In conclusion, this study highlights a novel function of DUSP6 in EOC and reveals 
that it may be involved in regulating chemoresponse. Targeting HE4 and/or DUSP6 in 
EOC may be an effective method of reversing chemoresistance and improving long-
term response rates in select patient populations.  
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Figure III.1 HE4 and DUSP6 Levels are Co-Dependent in Ovarian Cancer Cell Lines 
DUSP6 mRNA levels are higher in SKOV3-C1 (A) and OVCAR8-C5 (B) cells 
overexpressing HE4 than in null vector (NV) cells. *p<.05 (C) HE4 protein levels are 
reduced in cells with DUSP6 knockdown. (D) DUSP6 protein levels are reduced with 
HE4 knockdown. 
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Fig.III.1
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Figure III.2 Inhibition of DUSP6 Sensitizes Ovarian Cancer Cells to 
Chemotherapeutic Drugs.  
(A) SKOV3 cells exhibited reduced viability when co-treated with the DUSP6 
inhibitor BCI and either paclitaxel or carboplatin compared to either chemotherapeutic 
agent alone. (B) SKOV3 cells exhibited reduced viability when co-treated with the 
DUSP6 inhibitor BCI and either paclitaxel or carboplatin compared to either 
chemotherapeutic agent alone. Error bars represent standard deviation of 3 biological 
replicates in a single experiment. *p<0.05, ***p<.0005, ****p<.00005 
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Fig.III.2  
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Figure III.3 DUSP6 Inhibition Alters Expression of ERK Pathway Responsive Genes. 
(A-B) BCI opposes the effect of rHE4 on EGR1 levels in OVCAR8 and SKOV3 cells. 
EGR1 mRNA levels are higher in cells co-treated with BCI and chemotherapeutic 
drugs than in cells treated with chemotherapy alone. (C-D) BCI opposes the effect of 
rHE4 on EGR1 levels in OVCAR8 and SKOV3 cells. JUN mRNA levels are lower in 
cells co-treated with BCI and chemotherapeutic drugs than in cells treated with 
chemotherapy alone. n=2-3 independent experiments. 
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Fig.III.3 
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Figure III.4  
Figure 4. DUSP6 Levels are Higher in EOC Tissue than Normal Adjacent Tissue, and 
Correlate with HE4 Tissue Levels.  
(A) DUSP6 mean and maximum intensity staining is higher in serous EOC tissue 
(n=40) than in normal adjacent tissue (NAT) (n=7). Error bars represent deviation. 
*p<0.05 (B) Representative images of NAT and serous EOC DUSP6 staining.  (C) 
Correlation of DUSP6 and HE4 mean intensity. (D) Correlation of DUSP6 and HE4 
integrated optical density (IOD). Graph excludes one outlier data point for clarity (data 
is included in Spearman Rank Correlation calculation). 
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Fig.III.4  
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IV.I Abstract 
Epithelial Ovarian Cancer (EOC) is associated with dismal survival rates due to the 
fact that patients are frequently diagnosed at an advanced stage and eventually become 
resistant to traditional chemotherapeutics. Hence, there is a crucial need for new and 
innovative therapies. Septin-2, a member of the septin family of GTP binding proteins, 
has been characterized in EOC for the first time and represents a potential future 
target. Septin-2 was found to be overexpressed in serous and clear cell human patient 
tissue compared to benign disease. Stable septin-2 knockout clones developed in an 
ovarian cancer cell line exhibited a significant decrease in proliferation rates. 
Comparative label-free proteomic analysis of septin-2 knockout cells revealed 
differential protein expression of pathways associated with the TCA cycle, acetyl 
CoA, proteasome and spliceosome. Further validation of target proteins indicated that 
septin-2 plays a predominant role in post-transcriptional and translational 
modifications as well as cellular metabolism and are the first to suggest the potential 
novel role of septin-2 in promoting EOC tumorigenesis through these mechanisms.  
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IV.2 Introduction  
Epithelial Ovarian Cancer (EOC) is the most lethal gynecologic malignancy [1]. In 
2018, there will be an estimated 22,240 new cases of EOC diagnosed and 14,070 
deaths in the United States. While EOC accounts for only 2.5 % of all female cancers, 
it is responsible for 5% of all cancer deaths due to low disease survival rates [2].  
These dire statistics are attributed to the fact that the majority of patients are diagnosed 
at an advanced stage. In addition, while patients generally respond well to frontline 
platinum-based chemotherapy, chemoresistant recurrences are common [3]. Therefore, 
there is a strong need for novel early detection methods and targeted therapies for 
EOC patients.  
Septin-2 is a member of the septin family, a conserved family comprised of 13 GTP 
binding proteins [4]. Septins, which are structurally observed as rods and filaments, 
are vital to a number of cellular processes, including cytokinesis, vesicle trafficking, 
and exocytosis [5].  They are considered to be a fourth component of the cytoskeleton 
due to their association with actin, microtubules, and membranes [6]. Septins have 
been identified as having a role in neurodegenerative disease, since they were detected 
in brain tissue from patients with Alzheimer disease [7]. In addition, they have been 
reported to be involved in bacterial infections, Parkinson’s disease, and male infertility 
[8]. 
In more recent years, emphasis has been placed on investigating the role of septins in 
tumorigenesis [9]. Due to their natural function in scaffolding and membrane 
compartmentalization, it is plausible that they could also play a role in the 
organization of membrane associated proteins involved in diverse tumorigenic 
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signaling pathways [6]. Septin-9 is the best studied septin family member in 
relationship to cancer, and its methylation status is utilized as a biomarker in 
colorectal cancer [10].  However, there have also been numerous studies linking 
septin-2 to neoplasia. Thus far, septin-2 has been specifically implicated in Hodgkin’s 
lymphoma and biliary tract, gastric, hepatocellular, and breast cancer [11–15], but its 
role in EOC has not yet been investigated.  
In this study, we begin to elucidate septin-2’s function in EOC. As septins have been 
shown to have diverse roles in tumorigenesis, this is the first step in specifically 
defining septin-2’s contribution to EOC pathogenesis. To establish the clinical 
relevance of septin-2 in EOC, we first sought to compare levels of septin-2 in various 
histological pathologies of EOC versus benign disease. Furthermore, we present for 
the first time a global analysis of septin-2 mediated proteomics in EOC and describe 
signaling pathways most affected by septin-2 depletion. The results from this study lay 
the framework for future mechanistic studies to determine the precise role of septin-2 
in EOC.  
 
IV.3 Methods 
Cell Culture  
SKOV3 wild type (SKOV3WT) and OVCAR8 wild type (OVCAR8WT) cell lines 
were obtained from American Type Culture Collection (ATCC) and were cultured in 
Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin in a humidified incubator at 37°C/5% CO2.  
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Septin-2 silencing with shRNA  
shRNA for human HE4 (Santa Cruz Biotechnology, sc-40936-SH) or control shRNA 
(Santa Cruz Biotechnology, sc-108066) was transfected into SKOV3WT cells using 
Lipofectomine® 2000 (Invitrogen, 11668) following the manufacturer’s instructions. 
Individual single cells were selected by culturing under the pressure of 5 ug/mL of 
puromycin (Research products International, 58-58-2), and clonal populations were 
allowed to expand. Phenotypes of the clones were evaluated by western blotting using 
anti Septin-2 antibody (Novus Biologicals, NBP1-85212) 
 
Proliferation Assay 
SKOV3WT, Plasmid C, KO#9, and KO#11 were plated at equal densities in 
100x20mm plates. Cells were trypsinized at 72 and 96 hours, and replicates of three 
were counted using a hemocytometer to compare proliferation rates. The experiment 
was repeated three times and error bars represent standard deviation. Statistical 
significance was determined by an unpaired, two-tailed Student t-test, where p<.05 
was considered significant. 
 
Immunohistochemistry and confocal immunofluorescent microscopy  
Formalin-fixed paraffin embedded human ovarian tissue slides were obtained from the 
Women and Infants Pathology Department. The human ovarian tissue microarray was 
obtained from US Tissue Biomax (OV802a). Slides obtained from Women and Infants 
were baked at 65 °C for two hours, and the microarray for 20 minutes. All slides were 
subsequently washed in xylene, 100% ethanol, 95% ethanol, 70% ethanol, 
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deoxygenated water, and FTA Hemagglutination Buffer. Antigen retrieval was then 
performed using DAKO antigen retrieval solution (10x) (Agilent, S1699), heated to 95 
°C for 20 minutes. Slides were then blocked with 5% horse serum in FTA 
Hemagglutination Buffer and incubated overnight in primary Septin-2 antibody (Santa 
Cruz, sc-20408) at 4 °C. Secondary antibody, Alexa Fluora 488 (Thermo Fisher 
Scientific, A-11055) was then added to slides following incubation in the dark for one 
hour at room temperature. Slides were washed in between steps with FTA 
Hemagglutination Buffer and were cover-slipped with DAPI containing mounting 
medium (Vector Laboratories, H-1200).  Images were acquired using a Nikon E800 
microscope (Nikon Inc. Mellville, NY, USA) and an RT3 SPOT camera (Diagnostic 
Istruments, Sterling Heights, MI, USA). Random sampling of ten fields was based on 
DAPI staining. Mean intensity or integrated optical density (IOD), expressed as 
area*mean/1E+07, was acquired using a 40X objective. Statistical significance was 
determined by an unpaired, two-tailed Student t-test, where p<.05 was considered 
significant. 
 
Western Blot 
Protein was extracted from cell pellets in Cell Lysis Buffer (Cell Signaling, 9803) with 
1 mM of PMSF, according to the manufacturer’s protocol. The concentration of 
extracted proteins was determined by DC Protein Assay (Bio-Rad Laboratories, 
5000116). Western blot analysis was performed by loading equal amounts of protein 
boiled at 70 °C with Novex Sample Reducing Agent (Life Technologies, NP009) and 
NuPAGE LDS sample buffer (ThermoFisher Scientific, NP0007) into a 4–12 % 
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gradient NuPAGE Novex Bis-Tris gel [Life Technologies, NP0321BOX (mini), 
WG1402BX10 (midi)]. The gel was then transferred using a semi-dry transfer to 
methanol-activated 0.2 μm PVDF membranes (Bio-Rad, 162-0177) at 0.12-0.24A for 
1 h 20 m. Membranes were blocked in 5 % milk in phosphate-buffered saline with 
0.05 % Tween 20 (PBS-T) for 30 m at room temperature. Finally, membranes were 
incubated in primary antibody diluted in 5 % milk in PBS-T overnight at 4 °C, and 
then in secondary antibody diluted in 5 % milk in PBS-T for 1 h at room temperature, 
with PBS-T washes in between. Amersham ECL Prime Western Blot Detection 
System (GE Healthcare, RPN2232) was employed for detection of the HRP-tagged 
secondary antibodies. The Biorad Chemidoc MP Imaging System was used to image 
all blots. GAPDH was used as a loading control. Antibodies and respective dilutions 
used are as follows: 
GAPDH (cell signaling, 2118, [1:2000]) 
Septin-2(novus biologicals, NBP1-85212, [1:500]) 
LDHA(cell signaling, 3582S, [1:1000]) 
FASN (cell signaling, 3180S, [1:1000]) 
Enolase (santa cruz biotechnology, sc-100812 [1:500]) 
Transketolase (santa cruz biotechnology, sc-390179) [1:500]) 
 
Quantitative PCR 
RNA was extracted from cells by Trizol /LiCl precipitation. Total RNA (1000 ng) was 
then reverse transcribed into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad, 
1708890), following the manufacturer’s protocol. Quantitative PCR was performed in 
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triplicate by loading 1 μl cDNA reaction, 1 μM forward and reverse validated Septin-2 
primers (Origene HP232247), 10 μl SYBR Green (Applied Biosciences [ABI], 
4367659) and 5 μl RNAse-free water to each well. Samples were run using the ABI 
7500 Fast Real-Time PCR System. Data was then analyzed using the ΔΔCt method. 
All gene expression levels were normalized to 18 s rRNA.  
 
Densitometry  
Densitometry analysis of western blots was performed using image J. Blot images 
were analyzed in 8-bit JPEG format, using the “analyze gel” function. Relative band 
densities were normalized to GAPDH loading control.   
 
Sample preparation for LC-MS/MS analysis  
Cell pellets were subjected in lysis buffer (8 M urea, 1 mM sodium orthovanadate, 20 
mM HEPES, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, pH 8.0, 20 
min, 4°C), sonicated and cleared by centrifugation (14 000 × g, 15 min, 4°C). Protein 
concentration was measured (Pierce BCA Protein Assay, Thermo Fisher Scientific, IL, 
USA) and a total of 100 µg of protein per sample was subjected for trypsin digestion. 
Typtic peptides were desalted using C18 Sep-Pak plus cartridges (Waters, Milford, 
MA) and were lyophilized for 48 hours to dryness. The dried eluted peptides were 
reconstituted in buffer A (0.1 M acetic acid) at a concentration of 1 µg/µl and 5 µl was 
injected for each analysis.  
The LC-MS/MS was performed on a fully automated proteomic technology platform 
[16,17] that includes an Agilent 1200 Series Quaternary HPLC system (Agilent 
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Technologies, Santa Clara, CA) connected to a Q Exactive Plus mass spectrometer 
(Thermo Fisher Scientific, Waltham, MA). The LC-MS/MS set up was used as 
described earlier [18]. Briefly, the peptides were separated through a linear reversed-
phase 90 min gradient from 0% to 40% buffer B (0.1 M acetic acid in acetonitrile) at a 
flow rate of 3 µl /min through a 3 µm 20 cm C18 column. The electrospray voltage of 
2.0 kV was applied in a split flow configuration, and spectra were collected using a 
top-9 data-dependent method. Survey full scan MS spectra (m/z 400-1800) were 
acquired at a resolution of 70,000 with an AGC target value of 3×106 ions or a 
maximum ion injection time of 200 ms. The peptide fragmentation was performed via 
higher-energy collision dissociation with the energy set at 28 NCE. The MS/MS 
spectra were acquired at a resolution of 17,500, with a targeted value of 2×104 ions or 
a maximum integration time of 200 ms. The ion selection abundance threshold was set 
at 8.0×102 with charge state exclusion of unassigned and z =1, or 6-8 ions and 
dynamic exclusion time of 30 seconds. 
 
Bioinformatics analysis 
Peptide spectrum matching of MS/MS spectra of each file was searched against a 
species-specific databases (UniProt; downloaded 2/1/2015) using MASCOT v. 2.4 
(Matrix Science, Ltd, London, UK). A concatenated database containing “target” and 
“decoy” sequences was employed to estimate the false discovery rate (FDR) [19]. 
Msconvert from ProteoWizard (v. 3.0.5047), using default parameters and with the 
MS2Deisotope filter on, was employed to create peak lists for Mascot. The Mascot 
database search was performed with the following parameters: trypsin enzyme 
cleavage specificity, 2 possible missed cleavages, 10 ppm mass tolerance for precursor 
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ions, 20 mmu mass tolerance for fragment ions. Search parameters permitted variable 
modification of methionine oxidation (+15.9949 Da) and static modification of 
carbamidomethylation (+57.0215 Da) on cysteine. The resulting peptide spectrum 
matches (PSMs) were reduced to sets of unique PSMs by eliminating lower scoring 
duplicates. To provide high confidence, the Mascot results were filtered for Mowse 
Score (>20). Peptide assignments from the database search were filtered down to a 1% 
FDR by a logistic spectral score as previously described [19,20].  
 
Relative quantitation of the identified peptides  
Relative quantification of peptide abundance was performed via calculation of 
selected ion chromatograms (SIC) peak areas. Retention time alignment of individual 
replicate analyses was performed as previously described [21]. Peak areas were 
calculated by inspection of SICs using in-house software programmed in R 3.0 based 
on the Scripps Center for Metabolomics’ XCMS package (version 1.40.0). This 
approach performed multiple passes through XCMS’ central wavelet transformation 
algorithm (implemented in the centWave function) over increasingly narrower ranges 
of peak widths and used the following parameters: mass window of 10 ppm, minimum 
peak widths ranging from 2 to 20 seconds, maximum peak width of 80 seconds, signal 
to noise threshold of 10 and detection of peak limits via descent on the non-
transformed data enabled. SIC peak areas were determined for every peptide that was 
identified by MS/MS. In the case of a missing MS/MS for a particular peptide, in a 
particular replicate, the SIC peak area was calculated according to the peptide's 
isolated mass and the retention time calculated from retention time alignment. A 
minimum SIC peak area equivalent to the typical spectral noise level of 1000 was 
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required of all data reported for label-free quantitation. Individual SIC peak areas were 
normalized to the peak area of the standard synthetic peptide DRVYHPF that was 
exogenously spiked prior to reversed-phase elution into the mass spectrometer. 
Quantitative analysis was applied to replicate experiments. To select peptides that 
show a statistically significant change in abundance between control vs treatment 
cells, q-values for multiple hypothesis tests were calculated based on p-values from 
two-tailed unpaired Student’s t tests using the R package QVALUE as previously 
described [22,23]. 
 
IV.4 Results 
Septin-2 is overexpressed in EOC   
A preliminary proteomic study determined interacting partners of the clinical EOC 
biomarker HE4. It was noted that septin-2 was the most upregulated HE4-interacting 
protein (13-fold) in SKOV3 ovarian cancer cells overexpressing HE4 compared to null 
vector cells (data not shown). This finding prompted us to begin to characterize septin-
2’s role in EOC, as it had not been previously documented in the literature. To 
establish the clinical relevance of septin-2 in EOC, we evaluated its levels in EOC 
samples of a variety of histopathologies and compared these to levels in benign 
controls. Immunohistochemical analysis of septin-2 levels in a human ovarian tissue 
microarray comprising normal, serous, mucinous, clear cell, and dysgerminoma 
histopathologies revealed that mean intensity of the septin-2 staining was statistically 
significantly greater in serous EOC (703.3889 pixels) than in adjacent normal tissue 
(539 pixels) (p=0.0037) (Fig.1a). While all other histopatholgies exhibited higher 
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mean intensity levels of septin-2—mucinous (603 pixels), clear cell (821 pixels), and 
dysgerminoma (744 pixels)—compared to the normal adjacent tissue, none where 
considered statistically significant possibly due to low numbers of samples available.  
To further investigate expression levels of septin-2 in patient samples, 
immunohistochemistry of septin-2 was performed in EOC and benign tissue from our 
institution. Integrated optical density (IOD) was calculated for each sample, which 
revealed statistically significant higher levels in serous (721 area*mean/1E+06, 
p=0.04) (Fig 1b. and 1c.) and clear cell (31 area*mean/1E+06, p=0.009) 
histopathologies (Fig.1d. and 1e.) compared to respective benign controls (239 
area*mean/1E+06) and (6 area*mean/1E+06).  
 
Stable knockdown of septin-2 influences cell proliferation 
In order to study septin-2’s function in EOC, stable septin-2 knockout shRNA clones 
were generated in human serous ovarian SKOV3 wild type (WT) cells. Two clonal 
populations were employed for these studies—knockout 9 (KO9) and knockout 11 
(KO11)—based on confirmation of successful septin-2 downregulation. A stable line 
was also generated by clonal expansion of cells transfected with control shRNA, 
designated Plasmid C. To confirm the efficacy of knockdowns at the genomic level, 
qPCR was employed. Septin-2 levels in KO9 were 1.93- and 4.16-fold lower than WT 
and Plasmid C cells, respectively. Septin-2 levels in KO11 were 1.67- and 3.88-fold 
lower than WT and Plasmid C cells, respectively (Fig 2a).  
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To further validate successful knockdown of septin-2, protein levels were detected by 
western blot. We observed substantial decreases septin-2 levels in KO9 and KO11 
compared to the WT and Plasmid C controls (Fig 2b). Septin-2 levels in KO9 were 
decreased by 72% compared to WT and by 62.3% compared to Plasmid C. Septin-2 
levels in KO11 were reduced by 76.4% and 67.7% compared to WT and Plasmid C, 
respectively (Fig.2c). 
To begin to determine the consequence of septin-2 knockdown in SKOV3 cells, 
proliferation of the shRNA clones was evaluated. WT, Plasmid C, KO9, and KO11 
cells were seeded at equal cell densities and allowed to expand. The cells were 
trypsinized at 72 and 96 hours, and numbers of live cells in each clonal population 
were quantified (Fig 2d). At 72 hours, KO9 clones exhibited a 67.5% decrease in cell 
proliferation compared to WT, and a 60.4% decrease compared to Plasmid C. KO11 
clones demonstrated a 66.4% and 59.1% decrease in proliferation from respective WT 
and Plasmid C cell numbers. The 96-hour timepoint revealed a 51.1% reduction in 
KO9 cells compared to WT and a 39.3% reduction compared to Plasmid C. KO11 
cells showed a 62.6% and 53.6% decrease compared to WT and Plasmid C cells, 
respectively. All decreases in cell counts displayed by KO9 and KO11 at both 
timepoints were determined to be statistically significant (p<0.02). This finding 
strongly suggests that the downregulation of septin-2 has a profound impact on cell 
proliferation in EOC cells. 
Proteomic analysis of septin-2 knockdown in EOC cells 
A comparative label-free proteomic analysis was performed to examine global protein 
expression level differences resulting from the knockdown of septin-2. Interestingly, 
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significant differences in protein-peptide levels between control cells and septin-2 
knockouts was observed only in KO11 populations, even though our proliferation 
results demonstrated that KO9’s phenotype was similar to that of KO11. We 
concluded that it was possible that the knockdown resulted in less significant effects 
on protein levels, but still enough to affect proliferation, or that spontaneous loss of 
the knockdown had occurred during cell culture. Therefore, we proceeded with 
analysis using KO11 cells. As expected, a principal component analysis of three 
biological replicates of WT, Plasmid C, and KO11 revealed separate clusters when 
comparing principal component 1 and principal component 2 scores (Fig.3). In 
contrast, for KO9 sample, the 3 biological replicates were very scattered (Data not 
shown). Therefore, for any further analysis or validation process KO9 was not 
included.  
Mass spectrometry of the control and knockdown cells identified 19976 unique 
peptides corresponding to 3565 unique proteins. Of those, only one peptide/protein in 
Plasmid C exhibited an absolute fold change greater than 1 with a q-value < 0.05 
compared to WT (Fig 4a). This result allowed us to conclude that there was no 
significant difference between both control cell populations. Conversely, 5% of all 
peptides in KO11 cells revealed relative fold change greater than 1 (q<0.05) compared 
to WT cells. In addition, 93.5% of those peptides identified as exhibiting substantial 
expression differences displayed a lower peak area in KO11 than WT, indicating a 
majority of peptides was downregulated (Fig 4b). Representative examples of peak-
area of four peptide sequences from the proteins galetin-3 binding protein 
(LFALS3BP), transketolase (TKT), poly(A) binding protein (PABPC4), and enolase-
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1(ENO1) show differential expression between control and knockdown cells. 
KO11/WT peak area ratios were calculated for LFALS3BP (0.051, q=0.012), TKT 
(0.081, q=0.0012), PABPC4 (0.50, q=0.011), and ENO1 (632.7, q=0.30) (Fig 4c). It is 
interesting to note that, all four of these proteins have previously been shown to play a 
role in tumorigenesis [24–27]. Heat maps were constructed to illustrate the clustering 
of the 231 differentially expressed proteins in each of the three replicates of WT, 
Plasmid C, and KO11 (Fig 5a) and representative peptides in the most differentially 
expressed proteins (Fig 5b). Comparison of both heat maps reveals an overall similar 
pattern of peak-area quantitation, with many of the proteins and peptide sequences 
within KO11 exhibiting downregulation compared to WT and Plasmid C controls.  
Finally, gene ontology (GO) analysis with differentially expressed proteins showed 
enrichment of for, proteasomal/ubiquitin in the biological process category and RNA 
binding in the molecular function category (Fig 6). Enrichment was also noted for 
terms related to the ribonucleoprotein complex and cytosol in the cellular component 
category. KEGG pathway analysis revealed citric acid cycle (TCA cycle) and 
spliceosome enrichment among differentially expressed proteins (Fig 6).  
Representative proteins related to these pathways were further validated by 
immunoblot analysis. Enolase, LDHA, Transketolase, and FASN expression in WT 
and KO11 was examined via western blot. (Fig 7a.) Band density normalized to 
GAPDH revealed a 7.8% increase in Enolase expression from WT to KO11. A 
corresponding 24.2%, 52.6%, and 64.9% decrease was observed comparing WT and 
KO11 in LDHA, Transketolase and FASN levels respectively. (Fig 7b.)  
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IV.5 Discussion  
For the first time, we have characterized septin-2 function in EOC and examined its 
proteomic effects on a global level. Several biological pathways were found to be 
differentially regulated in septin-2 knockout ovarian cancer cells, exemplified by 
representative proteins from (Fig 4c.) Galectin-3 is a member of the β-galactoside 
binding protein family that is involved in diverse functions inherent to cancer, such as 
metastasis, immune surveillance, inflammation, apoptosis, molecular trafficking, and 
mRNA splicing [28]. Transketolase is a pentose phosphate pathway enzyme essential 
for cancer growth due to its ability to control NADPH production and counteract 
oxidative stress [26]. Poly(A) binding protein is a highly conserved protein that plays 
an important role in mRNA stabilization and translation [29], which controls cell 
growth, proliferation, and differentiation [30]. Enloase1, found to be differentially 
expressed in cancer, is a key glycolytic enzyme that catalyzes 2-phosphogylgerate to 
phosphoenolpyruvate in the last steps of the glycolytic catabolic pathway [31].  
Of these pathways identified, it was most expected that autophosphorylation and 
proteasomal/ubiquitin protein functions were affected by septin-2 knockdown. It has 
been previously established that proper control of septins’ phosphorylation status is 
required for the completion of cytokinesis [32]. In fungus, Meseroll et. al (2013) 
discovered that changes in specific phosphorylation sites on septins (Cdc3p and 
Cdc11p) leads to the disruption of higher order septin structures, indicating septin 
phosphorylation is also a vital regulator of their own structure formation [33].  
Similar to phosphorylation, ubiquitination represents another important septin post-
translational modification. Septins have an established role interacting with proteins 
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involved in degradation pathways, such as ubiquitin ligases and de-ubiquitylating 
enzymes, which modulates protein turnover [12,34,35]. Recently, it has also been 
reported that SUMOylation of human septins is a critical process contributing to 
proper septin filament bundling and cytokinesis [36]. Unlike ubiquitin, SUMO (small 
ubiquitin-like modifiers) modification does not always lead to protein degradation, as 
SUMOylation can also modulate localization, interaction, and activity of the target 
protein [37]. Ribet et.al (2017) reported that septin-7 is constitutively SUMOylated 
throughout the cell cycle, and septin variants that are unable to be SUMOylated halt 
septin bundle formation and lead to defects in cytokinesis, highlighting its crucial role 
in septin filament bundling and cell division [36].  
GO analysis revealed that septin-2 is also involved in post-transcriptional 
modifications, as the spliceosome pathway was found to be enriched among septin-2 
regulated proteins (Fig 6). This result suggests that septin-2 plays a major role in the 
editing of both precursor messenger RNA (pre-mRNA) and proteins. The 
spliceosome, a large molecular complex involved in the removal of non-coding introns 
from pre-mRNA, represents a potential oncogenic target as evidence has shown that 
tumors rely on normal spliceosome function for cell survival [38,39]. In addition, 
Poly(A) binding protein, which we reported as an example of a differentially 
expressed protein (Fig. 4c), is a translation initiation factor that binds to the mRNA 
3’poly(A) tail [30] and also influences cell growth and survival. Since we have shown 
that the knockdown of septin-2 promotes irregular expression of a multitude of 
pathways related to mRNA and protein modifications, it seems reasonable that its 
downregulation would also affect tumor cell growth. 
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 As the depletion of septins can lead to cytokinesis failures, it is logical that cellular 
proliferation would subsequently be affected. [36] In this study, we observed a 
reduction in proliferation with septin-2 knockdown. (Fig.2d) Corroborating results 
from our study in EOC, Zhang et. al (2016) treated breast cancer cells with the broad 
septin inhibitor forchlorfenuron(FCF) and also observed a decrease in cell 
proliferation [15], which they attributed to the suppression of  MEK and ERK1/2 
(extracellular signal-regulated kinase 1/2) signaling [15]. Another study showed that 
septin-8 interacts with MAPK5 (mitogen activated protein kinase 5), further 
suggesting that septins play a role in the MAPK/ERK pathway [40]. Septin-9 has also 
been implicated in cell proliferation, as a septin-9 variant SEPT9_i1 binds to c-Jun-N 
terminal kinase (JNK), preventing its degradation and therefore promoting tumor cell 
proliferation [4]. In  addition, another septin-9 variant SEPT9_i3 has been found to be 
phosphorylated by cell-cycle-dependent kinase 1 (CDK1), controlling entry into 
mitosis and promoting cell survival and proliferation [41]. These investigations 
highlight that septin-2, and septins in general, play an important role in cellular 
proliferation and potentially promote tumor growth.   
Interestingly, the most novel conclusion drawn from this investigation was the robust 
enrichment seen in cellular metabolism and energy dynamics in proteins affected by 
septin-2 downregulation. This novel finding regarding septin-2 is in agreement with 
previous studies reporting on septin functions related to energy metabolism. One study 
identified that fungal septins FaCdc3 and FaCdc12 are required for lipid metabolism 
[42]. In addition, septin-9 was found to induce lipid droplet growth through binding to 
phosphatidylinositol-5-phosphate(PtdIns5P), a phospholipid with a well-established 
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role in dynamics and intracellular membrane trafficking [43]. PtdIns5P binding in turn 
controls septin-9 filament formation and its interaction with microtubules [44]. 
Furthermore, septin-11 was found to be expressed in human adipocytes and 
upregulated in obese individuals. SEPT11 mRNA was positively correlated with 
markers of insulin resistance in adipose tissue, and silencing of septin-11 muted 
insulin signaling and insulin-induced lipid accumulation in adipocytes [45].   
Our findings, however, represent the first time a septin family member has been 
implicated in cellular metabolism as it relates to tumorigenesis. Acetyl-CoA, one of 
the pathways most differentially expressed by septin-2, is a key metabolic player that 
links glycolysis, fatty acid oxidation, ketogenesis, amino acid metabolism, the TCA 
cycle, and lipid synthesis [46]. In normoxic conditions, acetyl-CoA is derived from 
glucose. However, under hypoxic conditions like in cancer, acetyl-CoA has been to 
found to derive from acetate, suggesting that targeting the acetyl-CoA pathway in 
cancer could represent a viable treatment option [47]. The TCA cycle, another 
important metabolic pathway, was also deregulated in the septin-2 knockdown clones. 
While previous dogma stated that tumor cells do not utilize the TCA cycle for energy, 
it has now been found that some cancer cells with deregulated oncogenes and tumor 
suppressor genes actually do rely on the TCA cycle [48]. In addition, the metabolic 
proteins transketolase and enolase, which are involved in glycolysis and the pentose 
phosphate pathway, respectively, were found to be differentially expressed by septin-2 
inhibition (Fig 4c), demonstrating that septin-2 is involved in various facets of cellular 
metabolism within EOC. Pathways related to metabolism and energy production have 
previously been found to contribute to EOC tumorigenesis, as it has been shown that 
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glycolysis drives chemoresistance in EOC and that high levels of fatty acid synthase 
(FASN) contribute to tumor cell growth through the promotion of human epidermal 
growth factor [49,50]. Therefore, it can be hypothesized that the inhibition of septin-2 
would exhibit a therapeutic effect in EOC via suppression of tumor metabolic 
pathways. 
 Overall, our study demonstrates the novel finding that septin-2 is involved in EOC 
pathogenesis. This investigation represents a springboard for future studies to 
determine the efficacy of septin-2 inhibition, in addition to more clearly elucidating its 
diverse mechanistic pathways in EOC tumorigenesis. While our proteomics study was 
performed in a serous ovarian cancer cell line, it would be interesting to repeat the 
stable knockdown experiment in a clear cell EOC line, since septin-2 was also found 
to be overexpressed in this histopathology. Additionally, both in vitro and in vivo 
studies could be performed to confirm that inhibition of septin-2 affects cell viability 
and tumor growth in order to determine if targeting of septin-2 synergizes with 
platinum-based chemotherapeutics. 
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Figure IV. 1 Septin-2 is overexpressed in EOC  
(a.) Tissue Microarray analysis reveals that septin-2 is overexpressed 
significantly(p=.0037) in serous EOC compared to adjacent normal control. 
Mucinous, clear cell, and dysgerminoma all exhibited a non-significant increase in 
septin-2 expression (mean intensity) (b.) Staining of human EOC tissue showed a 
statistically significant higher(p=0.04) septin-2 expression in serous compared to 
benign serous. (c.) Representative images of Serous EOC staining (left panel) vs 
benign (right panel). (b.) Staining of human EOC tissue showed a statistically 
significant higher(p=0.009) septin-2 expression in clear cell compared to benign 
tissue. (e.) Representative images of clear cell EOC staining (left panel) vs benign 
(right panel). 
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Fig.IV.1(a) 
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Fig IV.1(b-e) 
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Figure IV.2 Stable septin-2 knockdown shows a decrease in proliferation 
 (A.) Gene expression levels of septin-2 in KO9 and KO11 where significantly 
decreased (p<0.01) compared to WT and plasmid c control levels. (B.) Septin-2 is 
decreased in KO9 and KO11 at the protein level. (C.) Relative band density of (B.).  
(D.) Proliferation rates of KO9 and KO11 were significantly lower (p<0.02) at both 72 
and 96 hours compared to control WT and plasmid c. 
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Fig.IV.2  
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Figure IV.3 Principal Component Analysis of CO 
WT, Plasmid C, and KO11 samples show clustering based on grouping. However, WT 
is more dispersed and shows overlap with Plasmid C. Visualization of principal 
component 1(PC1) versus principal component 2 (PC2). 
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Fig IV.3  
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Figure IV.4 Volcano plot of fold change versus q-value of peak area for distinct 
peptides 
Of the 19976 distinct peptides (3565 proteins) identified, (A) only one peptide/protein 
(0%, red in inset pie chart) in Plasmid C and (B) 5.0% peptides in KO11 showed large 
difference (absolute fold change more than 1, and q < 0.05) against WT. Nearly 93.5% 
peptides showed lower peak-area (down regulation) in KO11. (C) represents the 
examples of peak-area/expression levels in replicates for four peptides are shown: 1. 
Galectin-3-binding protein (LGALS3BP, K7EKQ5), 2. Transketolase (TKT, P29401), 
3. Poly(A) binding protein 4 (PABPC4, Q4VC03), 4. Enolase 1 (ENO1, P06733). The 
peptide sequence, KO11/WT peak-area ratio and respective q-values are listed for 
each protein. 
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Fig.IV.4 
 
 194 
Figure IV.5 Hierarchical clustering and heat map of differentially expressed proteins 
and peptides 
(A.) Clustering of the 231 differentially expressed proteins (B.) Peptides in most 
differentially expressed proteins, for example, Q9P2E9 (RRBP1, Ribosome binding 
protein 1) with 60 peptides, showing an overall similar pattern of peak-area 
quantitation.  
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Fig.IV.5  
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Figure IV.6 Gene ontology (GO) analysis  
Gene ontology (GO) analysis using DAVID (https://david.ncifcrf.gov/). Proteins with 
differential expression (n = 231, q < 0.05, in KO11 versus WT is compared with 
proteins (n = 3334) that showed no differential expression. Former showed enrichment 
for proteasomal/ubiquitin related GO terms (q << 0.05, Bonferroni) in biological 
process (BP) category. In cellular component (CC) and molecular function (MF) 
categories, differentially expressed proteins showed enrichment for ribonucleoprotein 
and RNA related terms. No enrichment was seen in molecular function category. 
Differentially expressed proteins showed enrichment for KEGG pathways relating to 
citrate cycle/energy and spliceosome. 
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Fig.IV.6  
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Figure IV.7 Verification of Enriched Proteins Identified by Proteome Analysis  
(A.) Western Blot analysis of protein expression validated in both WT and KO11 (B.) 
Relative Band Densities of proteins in (A.), normalized to GAPDH.   
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Fig.IV.7 
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             CHAPTER 7 
CONCLUSION 
 
Epithelial ovarian cancer (EOC) is such a deadly disease largely owing to the two 
major challenges of diagnosis and treatment. Ovarian cancer is detected at a late stage 
when tumor cells have already detached and metastasized directly into the peritoneal 
cavity, making it challenging for all lesions to be removed surgically [1]. Therefore, 
extensive disease remains in the body even after surgery. While treatment has evolved 
to include PARP inhibitors and anti-angiogenic therapies, prognosis remains poor. 
Immunotherapies for the treatment of cancer have recently garnered much attention, as 
it has been observed that the number of intratumoral T-cell numbers correlate to a 
better clinical outcome [2]. However, establishing a breakthrough immune target for 
ovarian cancer has been met with challenges, as the response rate remains low [3]. 
Therefore, a critical need for novel therapies for EOC still exists.  
HE4 plays a unique role in EOC as it has been implicated in both diagnosis and 
prognosis of the disease. As a clinical biomarker, HE4 represents a promising early 
detection method. Compared to the more established biomarker CA-125, it is less 
frequently elevated in benign disease and is potentially able to identify patients that 
are at high risk for primary platinum resistance [4]. While much is known about HE4 
clinically, far less is known about its biological functions in EOC. The goal of this 
investigation was to determine the mechanisms in which HE4 drives ovarian 
pathogenesis, and to ultimately provide evidence as to whether HE4 should be 
recommended as a therapeutic target for EOC.  
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As HE4 was initially suggested to have a potential role in innate immunity, [5] these 
studies aimed to better understand HE4’s function in tumor immunity. For the first 
time, this investigation has shown that HE4 is involved in promoting ovarian tumor 
immune evasion, through influencing expression of two proteins, osteopontin (OPN) 
and dual specificity phosphatase 6 (DUSP6). Subtractive hybridization revealed that 
when peripheral blood mononuclear cells (PBMCs) were treated with recombinant 
HE4, OPN was the most downregulated protein, and DUSP6 was the most 
upregulated.  
OPN is a secreted glycoprotein that has been identified as having important T helper 1 
(Th1) cytokine functions. [6]Specifically, it was discovered that HE4 suppresses OPN 
in CD3+ T cells, while also impairing the secretion of IL-12 and IFN-γ, two important 
cytokines downstream of OPN that promote T-cell survival [6,7].  Furthermore, when 
ovarian cancer cells were cultured with media from PBMCs cultured with recombinant 
HE4, those cells were less susceptible to cell death, which was reversed upon silencing 
of HE4. Also, in human EOC patient tissue, serum HE4 levels inversely correlated to 
the number of OPN positive T cells in patient tumors.  
The second objective in defining HE4’s role in tumor immunity was to delineate the 
effect of HE4’s upregulation of DUSP6. DUSP6 is an extracellular signal-regulated 
kinase (ERK) phosphatase that has been found to regulate CD4+ T cell activation and 
differentiation through the inhibition of T-cell receptor (TCR) dependent ERK 
activation [8]. Interestingly, upon testing HE4’s upregulation of DUSP6 in specific 
subsets of cells within PBMCs, the upregulation was found to be restricted to CD8+ 
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T-cells and CD56+ natural killer (NK) cells, and not CD4+ T cells. It was also 
discovered that HE4 promotes ERK ½ phosphorylation in these cell populations. Upon 
co-culture of PMBCs with ovarian tumor cells it was found that adding recombinant 
HE4 enhanced cell proliferation. However, this effect was attenuated by the addition 
of an allosteric DUSP6 inhibitor (BCI). PBMCs devoid of CD8+/CD56+ cells did not 
produce the same result, proving that CD8+ and CD56+ populations were solely 
responsible for the observed effects. This result was particularly interesting in light of 
HE4’s hypothesize role in innate immunity, since NK cells, as part of the innate 
immune response, have been found to play an important role in helping tumor cells 
escape immune surveillance [9]. 
These two studies indicate that through targeting of HE4, it may be possible to restore 
a normal tumor immune response. To confirm this, future directions include testing 
the inhibition of HE4 via a neutralizing antibody in an immune competent mouse 
model to see how this affects tumor burden. In addition, testing HE4 inhibition in vivo 
in combination with platinum-based chemotherapeutics and immune checkpoint 
inhibitors to determine synergistic effects is important. Results from these studies will 
be valuable, as many successful EOC regimens are combination therapies that produce 
higher response rates and lower resistance rates compared with monotherapies [10].  
Before HE4 can truly be recommended as a novel therapy that can remedy tumor 
immune evasion, results from these in vivo experiments should be obtained.  
The study of DUSP6 and HE4 in immune cells lead to an additional investigation that 
examined DUSP6’s role in epithelial ovarian cells. This was of particular interest since 
DUSP6 has not been well defined in cancer, and it has been published that HE4 
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interacts with the ERK signaling pathway in EOC [11–13]. This study confirmed that 
DUSP6 functions similarly to HE4 in EOC pathogenesis, as the inhibition of both 
factors promotes apoptosis in EOC cells. Furthermore, DUSP6 is overexpressed in 
serous EOC patient tissue and intratumoral levels of HE4 and DUSP6 correlate. Since 
it has been published that HE4 promotes chemoresistance in EOC [14], the effect of 
DUSP6 on platinum response was also evaluated. When DUSP6 was inhibited with 
BCI in combination with carboplatin and paclitaxel, it produced a synergistic response 
over single-agent chemotherapeutic. To assess downstream effects of this inhibition, it 
was shown that BCI altered genomic levels of the ERK related response genes early 
growth response protein 1 (EGR1), a strong promoter of apoptosis and proto-oncogene 
c-Jun [15]. EGR1 was upregulated in cells co-treated with BCI and either paclitaxel or 
carboplatin, compared to a single-agent treatment, while c-Jun expression was 
decreased upon co-treatment. This study was able to define a new role for DUSP6 
within EOC, indicating that targeting this factor is important both to restore proper 
tumor immune function and to overcome chemoresistance in EOC cells.  
Moreover, as HE4 has the ability to be detected in patient serum, it would be 
interesting to determine if DUSP6 could also be detected in patient blood. Additional  
future directions include establishing stable DUSP6 knockdown and overexpressing 
clones to test cancer related phenotypes. Furthermore, as HE4 overexpressing and 
stable knockout cell lines have been previously established, global genomic arrays 
could then be performed to establish similarities and differences between the 
overexpression and knockout populations of each factor. 
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Finally, the last part of this thesis sought to characterize the novel protein septin-2 in 
EOC. Septin-2 is a member of the septins protein family, which comprises 13 GTP 
binding proteins that play important roles in various cellular processes including 
cytokinesis [16,17]. Septin-2 was identified in a small proteomics study as most 
enriched with HE4 immunoprecipitation in HE4 overexpressing cells versus null 
vector cells. For the first time, this study revealed that septin-2 is overexpressed in 
both serous and clear cell EOC patient tissue. Establishment of stable knockout clones 
in an ovarian cell lines showed that proliferation was drastically decreased in septin-2 
knockout clones. Global proteome analysis was employed to determine the relevant 
pathways in which septin-2 is involved with in EOC, revealing that down regulation of 
septin-2 produced differential expression of major metabolic and cellular energy 
pathways.  
As this was a pilot study with the simple goal of defining septin-2 in EOC, more 
research needs to be completed in order to understand its mechanistic role in ovarian 
tumorigenesis. Future directions involve an in vivo study to determine if septin-2 
knockout lead to a decrease in tumor growth, alike to the reduction of cell proliferation 
observed in vitro. Furthermore, it will also be important to elucidate the mechanistic 
relationship between septin-2 and HE4, in addition to determining how septin-2 and 
HE4 interact with metabolic and cellular energy pathways. This is an especially 
original finding as both proteins have not been previously found to interact with 
cellular metabolism and may lead to new novel therapeutic targets for EOC.      
As a reputable clinical biomarker, HE4 is valuable in the diagnosis and prognosis of 
EOC; however, knowledge of its role in treatment of EOC is deficient in comparison.  
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Overall, this thesis compilation improves the understanding of HE4’s diverse 
biological function in EOC, through highlighting its role in the promotion of tumor 
immune dysfunction and characterizing novel interacting proteins. As there is a dire 
need for innovative targeted therapies for EOC patients, this thesis presents new 
evidence that inhibiting HE4 represents promise not only in downregulating molecular 
mechanisms that promote tumorigenesis, but also in restoration of normal tumor 
immune function. Furthermore, global genomic and proteomics analysis of differential 
HE4 levels revealed its relationship to novel factors that had not previously been 
characterized in EOC prior to this investigation. Taken as a whole, this dissertation 
offers original insights that emphasize the importance of HE4’s role in the 
pathogenesis of EOC.  
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